

**REMARKS**

Applicants reserve the right to prosecute non-elected subject matter in subsequent divisional applications.

**Restriction Requirement**

Applicants note that in the Restriction Requirement faxed on July 11, 2003, the Examiner requested selection of a single invention in order for the response to be complete (see paper No. 5, section 6). Thus, Applicants elected with traverse, to prosecute Group 6, which includes and is drawn to at least new claims 21, 22, 23 and 28-29 directed to SEQ ID NO:6.

**Unity of Invention Standard Should be Applied to the Instant Application**

Applicants reiterate their arguments pertaining to the unity of invention standard filed 10/6/03 as if reiterated in full. Applicants continue to assert that the polynucleotide of SEQ ID NO:25 which encodes the polypeptide of SEQ ID NO:6 should be examined in conjunction with SEQ ID NO:6 as indicated in MPEP 1850. MPEP 1850 provides, in the section entitled "Unity of Invention - Nucleotide Sequences," that "[n]ucleotide sequences encoding the same protein are considered to satisfy the unity of invention standard and will continue to be examined together." See page 1800-65, column 1.

Therefore, the nucleotide of SEQ ID NO:25, which encodes SEQ ID NO:6, currently under examination, should also be examined, as SEQ ID NO:26 encoding SEQ ID NO:6 is considered to satisfy the unity of invention standard.

**Rejoinder**

Claim 36 is a product by process claim depending from the method of use claim (claim 35) which should be rejoined and examined in compliance with Commissioner's Notice in the Official Gazette of March 26, 1996, entitled "Guidance on Treatment of Product and Process Claims in Light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)." Therefore, claim 36 should also be examined along with claims 21, 22, 24 and 32-33 directed to SEQ ID NO:6.

The method claims of claims 27-28, 34-35 and 37-39 are entitled to rejoinder upon allowance of a product claim per the Commissioner's Notice in the Official Gazette of March 26, 1996, entitled "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)" which sets forth the rules, upon allowance of a product claim, for rejoinder of process claims covering the same scope of products. See also M.P.E.P. 821.04 as follows:

Where product and process claims drawn to independent and distinct inventions are presented in the same application, applicant may be called upon under 35 U.S.C. 121 to elect claims to either the product or process. . . . The claims to the nonelected invention will be withdrawn from further consideration under 37 C.F.R. 1.142. . . . However, if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claim will be rejoined.

**Objections to the Claims**

Claim 21 was objected to because the article "an" was used improperly in claim 21 (b), line 1. The word "an" has been deleted from claim 21 (b), line 1. Therefore, the objection to claim 21 is rendered moot.

**Rejection under 35 U.S.C. § 101**

Applicants' invention is directed to *inter alia*, to a novel immunoglobulin superfamily protein, abbreviated as IGFAM-6, naturally-occurring amino acid sequences at least 90% identical to the amino acid sequence of SEQ ID NO:6, and biologically active and immunogenic fragments of SEQ ID NO:6. IGFAM-6 is a polypeptide sequence encoded by a gene that is expressed in humans. The novel polypeptide is demonstrated in the specification and in subsequent analyses *infra* to be a human junctional adhesion molecule (JAM) (Specification, Table 2, page 60). As such, the claimed invention has numerous practical, beneficial uses in the diagnosis of acquired and inherited disease, expression profiling, and drug development, none of which require knowledge of how the polypeptide actually functions. As a result of the benefits of these uses, the claimed invention already enjoys significant commercial success.

IGFAM-6 shares chemical and structural homology with human JAM3 (GI 13448825, of

record). In particular, JAM3 has been shown to function as a mediator of JAM2 adhesion to T cells (Arrate, et al., of record). The similarity of the claimed polypeptide to another polypeptide of known, undisputed utility by itself demonstrates utility beyond the reasonable probability required by law. IGFAM-6 is, in that regard, human JAM3.

Claims 21-22, 24 and 32-33 stand rejected under 35 U.S.C. §§ 101 and 112, first paragraph, based on the allegation that the claimed invention lacks patentable utility. The rejection alleges in particular that:

- the claimed invention is not supported by either a specific and/or substantial asserted utility or a well established utility.
- The instant application does not discloses the biological role of the polypeptide or its significance.

**The rejection of claims 21-22, 24 and 32-33 is improper, as the inventions of those claims have a patentable utility as set forth in the instant specification, and/or a utility well-known to one of ordinary skill in the art.**

The invention at issue, identified in the patent application as immunoglobulin protein, abbreviated as IGFAM-6, is a polypeptide encoded by a gene that is expressed in nervous, reproductive and cardiovascular tissues of humans. The novel polypeptide is demonstrated in the specification to be a member of the class of immunoglobulin superfamily proteins, whose biological functions include a structural role in the control of monocyte migration across epithelium or endothelium to sites of inflammation (see Specification, page 4, lines 9-19). As such, the claimed invention has numerous practical, beneficial uses in toxicology testing, drug development, and the diagnosis of disease, none of which require knowledge of how the polypeptide actually functions. As a result of the benefits of these uses, the claimed invention already enjoys significant commercial success.

The similarity of the claimed polypeptide to another polypeptide of known, undisputed utility by itself demonstrates utility beyond the reasonable probability required by law. IGFAM-6 is, in that regard, homologous to murine JAM (see Specification, Table 2, column 6, page 60) and human JAM3 (gi13448825, of record). Murine JAM protein appears to play a structural role in the control of monocyte migration across epithelium or endothelium to site of inflammation and is situated at tight

junctions occurring between adjacent epithelial or endothelial cells (see Specification, page 4, lines 11-14). Human JAM3 has been demonstrated to function as a mediator of JAM2 adhesion to T cells (Arrate et al., of record). In particular, IGFAM-6 and human JAM3 share more than 99% sequence identity over 310 amino acid residues.

This is more than enough homology to demonstrate a reasonable probability that the utility of both murine JAM and human JAM3 can be imputed to the claimed invention. It is well-known that the probability that two unrelated polypeptides share more than 40% sequence homology over 70 amino acid residues. Brenner et al., Proc. Natl. Acad. Sci. U.S.A. 95:6073-78 (1998) (Reference No. 11). Given homology in excess of 40% over many more than 70 amino acid residues the probability that the claimed polypeptide is related to human JAM3 is, accordingly, very high. There is, in addition, direct proof of the utility of the claimed invention.

Applicants further submit with this Response three expert Declarations under 37 C.F.R. § 1.132, with respective attachments, and 10 scientific references. The Rockett Declaration, Bedilion Declaration, Iyer Declaration, and the 10 references fully establish that, prior to the December 22, 1998 filing date of the Yue '635 application, it was well-established in the art that:

expression analysis is useful, *inter alia*, in drug discovery and lead optimization efforts; in toxicology, particularly toxicology studies conducted early in drug development efforts; and in phenotypic characterization and categorization of cell types, including neoplastic cell types;

expression analysis can be performed by measuring expression of either proteins or of their encoding transcripts;

it is not necessary that the biological function of a gene be known for measurement of its expression to be useful in drug discovery and lead optimization analyses, toxicology, or molecular phenotyping experiments;

antibodies can routinely be prepared that specifically identify the protein immunogen; used as gene expression probes, such antibodies generate a signal that is specific to the protein, that is, produce a gene-specific expression signal;

each additional gene-specific probe used as a tool in expression analysis provides an additional gene-specific signal that could not otherwise have been detected, giving a more comprehensive, robust, higher resolution, statistically more significant, and thus more useful expression pattern in such analyses than would otherwise have been

possible;

biologists, such as toxicologists, recognize the increased utility of more comprehensive, robust, higher resolution, statistically more significant results, and thus want each newly identified expressed gene to be included in such an analysis;

failure of a probe to detect changes in expression of its cognate gene (because such changes did not occur in a particular experiment) does not diminish the usefulness of the probe as a research tool, because such information is itself useful; and

failure of a probe completely to detect its cognate transcript in any particular expression analysis experiment (because the protein is not normally expressed in that sample) does not deprive the probe of usefulness to the community of users who would use it as a research tool.

Applicants file herewith:

1. the Declaration of John C. Rockett, Ph.D., under 37 C.F.R. § 1.132, with Exhibits A-Q (hereinafter the "Rockett Declaration");
2. the Declaration of Tod Bedilion, Ph.D., under 37 C.F.R. § 1.132 (hereinafter the "Bedilion Declaration");
3. the Declaration of Vishwanath R. Iyer, Ph.D., under 37 C.F.R. § 1.132 with Exhibits A-E (hereinafter the "Iyer Declaration"); and
4. 10 references published before the December 22, 1998 filing date of the Yue '635 application,:
  - a) PCT application WO 95/21944, SmithKline Beecham Corporation, Differentially expressed genes in healthy and diseased subjects (August 17, 1995) (Reference No. 1)
  - b) PCT application WO 95/20681, Incyte Pharmaceuticals, Inc., Comparative gene transcript analysis (August 3, 1995) (Reference No. 2)
  - c) M. Schena et al., Quantitative monitoring of gene expression patterns with a complementary DNA microarray, Science 270:467-470 (October 20, 1995) (Reference No. 3)
  - d) PCT application WO 95/35505, Stanford University, Method and apparatus for fabricating microarrays of biological samples (December 28, 1995) (Reference No. 4)
  - e) U.S. Pat. No. 5,569,588, M. Ashby et al., Methods for drug screening (October 29, 1996) (Reference No. 5)

- f) R. A. Heller al., Discovery and analysis of inflammatory disease-related genes using cDNA microarrays, Proc. Natl. Acad. Sci. USA 94:2150 - 2155 (March 1997) (Reference No. 6)
- g) PCT application WO 97/13877, Lynx Therapeutics, Inc., Measurement of gene expression profiles in toxicity determinations (April 17, 1997) (Reference No. 7)
- h) Acacia Biosciences Press Release (August 11, 1997) (Reference No. 8)
- i) V. Glaser, Strategies for Target Validation Streamline Evaluation of Leads, Genetic Engineering News (September 15, 1997) (Reference No. 9)
- j) J. L. DeRisi et al., Exploring the metabolic and genetic control of gene expression on a genomic scale, Science 278:680 - 686 (October 24, 1997) (Reference No. 10)

The Patent Examiner contends that the claimed polypeptide cannot be useful without precise knowledge of its biological function. But the law never has required knowledge of biological function to prove utility. It is the claimed invention's uses, not its functions, that are the subject of a proper analysis under the utility requirement.

In any event, as demonstrated by the Rockett Declaration, the Bedilion Declaration, and the Iyer Declaration, the person of ordinary skill in the art can achieve beneficial results from the claimed polypeptide in the absence of any knowledge as to the precise function of the protein. The uses of the claimed polypeptide for gene and protein expression monitoring applications including toxicology testing are in fact independent of its precise function.

## I. The Applicable Legal Standard

To meet the utility requirement of sections 101 and 112 of the Patent Act, the patent applicant need only show that the claimed invention is "practically useful," *Anderson v. Natta*, 480 F.2d 1392, 1397, 178 USPQ 458 (CCPA 1973) and confers a "specific benefit" on the public. *Brenner v. Manson*, 383 U.S. 519, 534-35, 148 USPQ 689 (1966). As discussed in a recent Court of Appeals for the Federal Circuit case, this threshold is not high:

An invention is "useful" under section 101 if it is capable of providing some identifiable benefit. See *Brenner v. Manson*, 383 U.S. 519, 534 [148 USPQ 689] (1966);

*Brooktree Corp. v. Advanced Micro Devices, Inc.*, 977 F.2d 1555, 1571 [24 USPQ2d 1401] (Fed. Cir. 1992) (“to violate Section 101 the claimed device must be totally incapable of achieving a useful result”); *Fuller v. Berger*, 120 F. 274, 275 (7th Cir. 1903) (test for utility is whether invention “is incapable of serving any beneficial end”).

*Juicy Whip Inc. v. Orange Bang Inc.*, 51 USPQ2d 1700 (Fed. Cir. 1999).

While an asserted utility must be described with specificity, the patent applicant need not demonstrate utility to a certainty. In *Stiftung v. Renishaw PLC*, 945 F.2d 1173, 1180, 20 USPQ2d 1094 (Fed. Cir. 1991), the United States Court of Appeals for the Federal Circuit explained:

An invention need not be the best or only way to accomplish a certain result, and it need only be useful to some extent and in certain applications: “[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding lack of utility.” *Envirotech Corp. v. Al George, Inc.*, 730 F.2d 753, 762, 221 USPQ 473, 480 (Fed. Cir. 1984).

The specificity requirement is not, therefore, an onerous one. If the asserted utility is described so that a person of ordinary skill in the art would understand how to use the claimed invention, it is sufficiently specific. See *Standard Oil Co. v. Montedison, S.p.a.*, 212 U.S.P.Q. 327, 343 (3d Cir. 1981). The specificity requirement is met unless the asserted utility amounts to a “nebulous expression” such as “biological activity” or “biological properties” that does not convey meaningful information about the utility of what is being claimed. *Cross v. Iizuka*, 753 F.2d 1040, 1048 (Fed. Cir. 1985).

In addition to conferring a specific benefit on the public, the benefit must also be “substantial.” *Brenner*, 383 U.S. at 534. A “substantial” utility is a practical, “real-world” utility. *Nelson v. Bowler*, 626 F.2d 853, 856, 206 USPQ 881 (CCPA 1980).

If persons of ordinary skill in the art would understand that there is a “well-established” utility for the claimed invention, the threshold is met automatically and the applicant need not make any showing to demonstrate utility. Manual of Patent Examining Procedure at § 706.03(a). Only if there is no “well-established” utility for the claimed invention must the applicant demonstrate the practical benefits of the invention. *Id.*

Once the patent applicant identifies a specific utility, the claimed invention is presumed to possess it. *In re Cortright*, 165 F.3d 1353, 1357, 49 USPQ2d 1464 (Fed. Cir. 1999); *In re Brana*, 51 F.3d 1560, 1566; 34 USPQ2d 1436 (Fed. Cir. 1995). In that case, the Patent Office bears the

burden of demonstrating that a person of ordinary skill in the art would reasonably doubt that the asserted utility could be achieved by the claimed invention. *Id.* To do so, the Patent Office must provide evidence or sound scientific reasoning. *See In re Langer*, 503 F.2d 1380, 1391-92, 183 USPQ 288 (CCPA 1974). If and only if the Patent Office makes such a showing, the burden shifts to the applicant to provide rebuttal evidence that would convince the person of ordinary skill that there is sufficient proof of utility. *Brana*, 51 F.3d at 1566. The applicant need only prove a “substantial likelihood” of utility; certainty is not required. *Brenner*, 383 U.S. at 532.

**II. Diagnosis, treatment, or prevention of cancer, immune system disorders and infections are sufficient utilities under 35 U.S.C. §§ 101 and 112, first paragraph**

The claimed invention meets all of the necessary requirements for establishing a credible utility under the Patent Law: There are “well-established” uses for the claimed invention known to persons of ordinary skill in the art, and there are specific practical and beneficial uses for the invention disclosed in the patent application’s specification. These uses are explained, in detail, in the Rockett Declaration, Bedilion Declaration, and Iyer Declaration accompanying this Response. Objective evidence, not considered by the Patent Office, further corroborates the credibility of the asserted utilities.

**A. The similarity of the claimed polypeptide to another of undisputed utility demonstrates utility**

Because there is a substantial likelihood that the claimed IGFAM-6 is functionally related to murine JAM, a polypeptide of undisputed utility (see Specification, page 4, lines 11-15; page 60, Table 2), and to human JAM3 (see response filed 10/6/03), there is by implication a substantial likelihood that the claimed polypeptide is similarly useful. Applicants need not show any more to demonstrate utility. *In re Brana*, 51 F.3d at 1567.

It is undisputed, and readily apparent from the patent application that the claimed protein is a JAM protein as evidenced by the presence of a signal peptide and two immunoglobulin (Ig) domains (see Specification, Table 2, page 60), and also evident in the alignments submitted on 10/6/03, that the claimed polypeptide shares more than 99% sequence identity over 310 amino acid residues with human JAM. Applicants taught in the specification that murine JAM contains two Ig domains and is 300

amino acids in length. One of skill in the art would conclude that more likely than not that SEQ ID NO:6 is the human homolog of murine JAM. This is more than enough homology to demonstrate a reasonable probability that the utility of human JAM3 can be imputed to the claimed invention. Given homology in excess of 40% over **many** more than 70 amino acid residues, the probability that the claimed polypeptide is related to murine JAM is, accordingly, very high.

The Examiner must accept the Applicants' demonstration that the homology between the claimed invention and both murine JAM and human JAM3 demonstrates utility by a reasonable probability unless the Examiner can demonstrate through evidence or sound scientific reasoning that a person of ordinary skill in the art would doubt utility. *See In re Langer*, 503 F.2d 1380, 1391-92, 183 USPQ 288 (CCPA 1974). The Examiner has not provided sufficient evidence or sound scientific reasoning to the contrary.

While the Examiner has cited literature, Attwood (Science 2000: 290:471-473), Skolnick et al. (Trends in Biotech. 2000:18(1):34-39) and Metzler et al. (Nature Structural Biol. 1997: 4:527-531), identifying some of the difficulties that may be involved in predicting protein function, none suggest that functional homology cannot be inferred by a reasonable probability in this case. Importantly, none contradict Brenner's basic rule that sequence homology in excess of 40% over 70 or more amino acid residues yields a high probability of functional homology as well. The cited references also fail to rebut Applicants' assertion that the presence of Ig domains and a signal peptide in the claimed protein establish that the protein is an immunoglobulin. At most, these articles individually and together stand for the proposition that it is difficult to make predictions about function with certainty. The standard applicable in this case is not, however, proof to certainty, but rather proof to reasonable probability.

Additionally, the Examiner has cited Tsukita et al (Nat Rev Mol Cell Biol. 2(4):285-293, 2001), who alleged that knowledge of JAM function is still fragmentary. However, knowledge of JAM functioning in the extravasation of monocytes through endothelial cells did exist prior to Applicants' priority date, December 22, 1998. Tsukita had cited Martin-Padura et al. (J. Cell Biol. 142, 117-127 (1998, of record) who published their findings regarding JAM activity. Martin-Padura reported that JAM modulates monocyte transmigration. Modulation of monocytes is indeed a function, and is an important function with respect to the inflammatory response. Thus, JAM had an established utility, involvement in the immune response, specifically extravasation of monocytes through endothelial cells,

at the time the priority application was filed, December 22, 1998 and the Examiner has not presented evidence to rebut Applicants' asserted utility for the claimed protein.

**B. The uses of IGFAM-6 for toxicology testing, drug discovery, and disease diagnosis are practical uses that confer "specific benefits" to the public**

The claimed invention has specific, substantial, real-world utility by virtue of its use in toxicology testing, drug development and disease diagnosis through gene and protein expression profiling. These uses are explained in detail in the accompanying Rockett Declaration, Bedilion Declaration, and Iyer Declaration. The claimed invention is in fact a useful tool in two-dimensional polyacrylamide gel electrophoresis ("2-D PAGE") analysis and western blots used to monitor protein expression and assess drug toxicity.

This United States patent application is the National Stage of International Application No. US99/27566, filed November 19, 1999, and published in English as WO 00/29583 on 25 May 2000, which claims the benefit under 35 U.S.C. § 119(e) of provisional application U.S. Ser. No. 60/113,635, filed December 22, 1998 (hereinafter the Yue '635 application), among others. The Yue '635 application contains the same disclosure with respect to the claimed invention as the Yue '805 application. For the sake of convenience, Applicants cite to and discuss the Yue '805 specification below on the understanding that the descriptions in that specification have the December 22, 1998 priority date of the Yue '635 application. The SEQ ID NO:6 and SEQ ID NO:25 sequences recited in the Yue '805 application claims were first disclosed in the Yue '635 application and listed as SEQ ID NO:6 and SEQ ID NO:27, respectively, in the Yue '635 application.

In his Declaration, Dr. Rockett explains the many reasons why a person skilled in the art in 1998 would have understood that any expressed polypeptide or expressed polynucleotide is useful for a number of gene and protein expression monitoring applications, *e.g.*, in 2-D PAGE technologies or cDNA microarrays, in connection with the development of drugs and the monitoring of the activity of such drugs. (Rockett Declaration at, *e.g.*, ¶¶ 10-18).

It is widely understood among molecular and cellular biologists that protein expression levels provide complementary profiles for any given cell and cellular state. [Rockett Declaration, ¶ 11.]

Thus, as with nucleic acid microarrays, the greater the number of proteins detectable, the greater the power of the technique; the absence or failure of a protein to change in expression levels does not diminish the usefulness of the method; and prior knowledge of the biological function of the protein is not required. As applied to protein expression profiling, these principles have been well understood since at least as early as the 1980s. [Rockett Declaration, ¶ 14.]

It is my opinion, therefore, based on the state of the art in toxicology at least since the mid-1990s -- and as regards protein profiling, even earlier -- that disclosure of the sequence of a new . . . protein, with or without knowledge of its biological function, would have been sufficient information for a toxicologist to use the . . . protein in expression profiling studies in toxicology.<sup>1</sup> [Rockett Declaration, ¶ 18.]

In his Declaration, Dr. Bedilion explains why a person of skill in the art in 1998 would have understood that any expressed polynucleotide is useful for gene expression monitoring applications using cDNA microarrays. (Bedilion Declaration, e.g., ¶¶ 4-7.) In his Declaration, Dr. Iyer explains why a person of skill in the art in 1998 would have understood that any expressed polynucleotide is useful for gene expression monitoring applications using cDNA microarrays, stating that “[t]o provide maximum versatility as a research tool, the microarray should include – and as a biologist I would want my microarray to include – each newly identified gene as a probe.” (Iyer Declaration, ¶ 9.)

**C. The use of the claimed polypeptide in gene and protein expression monitoring applications using 2-D PAGE gels is disclosed in the Specification and is well known in the art**

As described in the Specification and as well known in the art at the time of filing, the claimed polypeptide can be used in gene and protein expression analysis techniques such as 2-D PAGE gels and western blots. Using the claimed invention with these techniques, persons of ordinary skill in the art can better assess, for example, the potential toxic effect of a drug candidate.

2-D PAGE technologies were developed during the 1980s. Since the early 1990s, 2-D PAGE has been used to create maps showing the differential expression of proteins in different cell types or in

---

<sup>1</sup>“Use of the words ‘it is my opinion’ to preface what someone of ordinary skill in the art would have known does not transform the factual statements contained in the declaration into opinion testimony.” *In re Alton*, 37 USPQ2d 1578, 1583 (Fed. Cir. 1996).

similar cell types in response to drugs and potential toxic agents. Each expression pattern reveals the state of a tissue or cell type in its given environment, e.g., in the presence or absence of a drug. By comparing a map of cells treated with a potential drug candidate to a map of cells not treated with the candidate, for example, the potential toxicity of a drug can be assessed.

The claimed invention makes 2-D PAGE analysis a more powerful tool for toxicology and drug efficacy testing. A person of ordinary skill in the art can derive more information about the state or states or tissue or cell samples from 2-D PAGE analysis with the claimed invention than without it.

**1. Disclosure of gene and protein expression monitoring assays in the Specification**

The Yue '635 application discloses that the polynucleotide sequences disclosed therein, including the polynucleotides encoding the SEQ ID NO:6 polypeptide, are useful as probes in chip-based technologies. It further teaches that the chip-based technologies can be used "for the detection and/or quantification of nucleic acid or protein sequences" (Yue '805 application at page 28).

The Yue '805 application also discloses that the SEQ ID NO:6 polypeptide is useful in protein expression detection technologies. The Yue '805 application states that "[i]mmunological methods for detecting and measuring the expression of IGFAM using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS)" (Yue '805 application at page 28). Furthermore, the Yue '805 application discloses that "[a] variety of protocols for measuring IGFAM, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of IGFAM expression. Normal or standard values for IGFAM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to IGFAM under conditions suitable for complex formation" (Yue '805 application at page 40).

Furthermore, the Yue '805 disclosure regarding the uses of the SEQ ID NO:6 polypeptide for protein expression monitoring applications is not limited to the use of that protein in 2-D PAGE maps. For one thing, the Yue '805 disclosure regarding the technique used in gene and protein expression monitoring applications is broad (Yue '805 application at, e.g., page 28, lines 20-24).

In addition, the Yue '805 specification repeatedly teaches that the protein described therein (including the SEQ ID NO:6 polypeptide) may desirably be used in any of a number of long established

“standard” techniques, such as ELISA or western blot analysis, for conducting protein expression monitoring studies. See, e.g.:

(a) Yue '635 application at page 28, lines 25-28 (“Immunological methods for detecting and measuring the expression of IGFAM using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS)’);

(b) Yue '635 application at page 40, lines 5-12 (“A variety of protocols for measuring IGFAM, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of IGFAM expression. Normal or standard values for IGFAM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to IGFAM under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of IGFAM expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease’).

## **2. Disclosure of gene and protein expression monitoring assays in the art**

A number of published articles and patent documents provide evidence that gene and protein expression monitoring techniques were well-known before the December 22, 1998 filing date of the Yue '635 application.

At the time of filing the Yue '635 application, it was well known in the art that gene and protein expression analyses also included two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) technologies, which were developed during the 1980s, as exemplified by the Anderson 1991 and 1995 articles (Reference No. 12 and Reference No. 13). The Anderson 1991 article teaches that a 2-D PAGE map has been used to connect and compare hundreds of 2-D gels of rat liver samples from a variety of studies including regulation of protein expression by various drugs and toxic agents (Reference No. 12 at page 907). The Anderson 1991 article teaches an empirically-determined standard curve fitted to a series of identified proteins based upon amino acid chain length (Reference No. 12 at page 911) and how that standard curve can be used in protein expression analysis. The

Anderson 1991 article teaches that “there is a long-term need for a comprehensive database of liver proteins” (Reference No. 12 at page 912).

Wilkins, for example, describes how 2-D gels are used to define proteins present in various tissues and measure their levels of expression, the data from which is in turn used in databases:

For proteome projects, the aim of [computer-aided 2-D PAGE] analysis . . . is to catalogue all spots from the 2-D gel in a qualitative and if possible quantitative manner, so as to define the number of proteins present and their levels of expression. Reference gel images, constructed from one or more gels, for the basis of two-dimensional gel databases. (Wilkins, Reference No. 13, page 26.)

The toxicity (or lack of toxicity) of any proposed drug is one of the most important criteria to be considered and evaluated in connection with the development of the drug. Good drugs are not only potent, they are specific. This means that they have strong effects on a specific biological target and minimal effects on all other biological targets. Ascertaining that a candidate drug affects its intended target, and identification of undesirable secondary effects (i.e., toxic side effects), had been for many years among the main challenges in developing new drugs. The ability to determine which genes are positively affected by a given drug, coupled with the ability to quickly and at the earliest time possible in the drug development process identify drugs that are likely to be toxic because of their undesirable secondary effects, have enormous value in improving the efficiency of the drug discovery process, and are an important and essential part of the development of any new drug. In fact, the desire to identify and understand toxicological effects using the experimental assays described above led Dr. Leigh Anderson to found the Large Scale Biology Corporation in 1985, in order to pursue commercial development of the 2-D electrophoretic protein mapping technology he had developed. In addition, the company focused on toxicological effects on the proteome as clearly demonstrated by its goals and by its senior management credentials described in company documents (see Reference No. 18 at pages 1, 3, and 5).

The Celis article stated that “protein databases are expected to foster a variety of biological information . . . -- among others, . . . drug development and testing” (See Reference No. 15, page 2200, second column). The Franzen article shows that 2-D PAGE maps were used to identify proteins in clinical tumor material (See Reference No. 16). The Yue ‘803 application clearly discloses that

expression of IGFAM is associated with, e.g., proliferating tissues, cancerous tissue and with hematopoiesis, inflammation (Yue '803 application at page 30, lines 25-27. The Bjellqvist article showed that a protein may be identified accurately by its positional coordinates, namely molecular mass and isoelectric point (See Reference No. 17). The Yue '635 application clearly disclosed SEQ ID NO:6 from which it would have been routine for one of skill in the art to predict both the molecular mass and the isoelectric point using algorithms well known in the art at the time of filing.

Expressed proteins are useful for 2-D PAGE analysis in toxicology expression studies for a variety of reasons, particularly for purposes relating to providing controls for the 2-D PAGE analysis, and for identifying sequence or post-translational variants of the expressed polypeptides in response to exogenous compounds. (E.g., Wilkins, page 40 and Celis, page 2204.)

### **3. Conclusion**

Thus a person skilled in the art on December 22, 1998, who read the Yue '635 specification, would have routinely and readily appreciated that the SEQ ID NO:6 polypeptide disclosed therein would be useful for conducting gene and protein expression monitoring analyses using 2-D PAGE mapping or western blot analysis or any of the other traditional membrane-based protein expression monitoring techniques that were known and in common use many years prior to the filing of the Yue '635 application. For example, a person skilled in the art on December 22, 1998 would have routinely and readily appreciated that the SEQ ID NO:6 polypeptide would be a useful tool in conducting protein expression analyses, using the 2-D PAGE mapping or western analysis techniques, for the development of new drugs and monitoring the activities of drugs for such purposes as evaluating their efficacy and toxicity.

### **D. The use of polypeptides expressed by humans as tools for toxicology testing, drug discovery, and the diagnosis of disease is now “well-established”**

The technologies made possible by expression profiling using polypeptides are now well-established. The technical literature recognizes not only the prevalence of these technologies, but also their unprecedented advantages in drug development, testing and safety assessment. These technologies include toxicology testing, e.g., as described by Rockett and Iyer in their Declarations.

Toxicology testing is now standard practice in the pharmaceutical industry. See, e.g., John C. Rockett, et. al., Differential gene expression in drug metabolism and toxicology: practicalities, problems, and potential, Xenobiotica 29:655-691 (July 1999) (Rockett Declaration, Exhibit C):

Knowledge of toxin-dependent regulation in target tissues is not solely an academic pursuit as much interest has been generated in the pharmaceutical industry to harness this technology in the early identification of toxic drug candidates, thereby shortening the developmental process and contributing substantially to the safety assessment of new drugs. (Rockett Declaration, Exhibit C, page 656)

To the same effect are several other scientific publications, including Emile F. Nuwaysir, et al., Microarrays and toxicology: The advent of toxicogenomics, Molecular Carcinogenesis 24:153-159 (1999) (Reference No. 19); Sandra Steiner and N. Leigh Anderson, Expression profiling in toxicology -- potentials and limitations, Toxicology Letters 112-13:467-471 (2000) (Reference No. 20).

The more genes – and, accordingly, the polypeptides they encode -- that are available for use in toxicology testing, the more powerful the technique. Control genes are carefully selected for their stability across a large set of array experiments in order to best study the effect of toxicological compounds. See attached email from the primary investigator of the Nuwaysir paper, Dr. Cynthia Afshari to an Incyte employee, dated July 3, 2000, as well as the original message to which she was responding (Reference No. 21) Thus, there is no expressed gene which is irrelevant to screening for toxicological effects, and all expressed genes have a utility for toxicological screening.

Further evidence of the well-established utility of all expressed polypeptides and polynucleotides in toxicology testing is found in U.S. Pat. No. 5,569,588 (Reference No. 5) and published PCT applications WO 95/21944 (Reference No. 1), WO 95/20681 (Reference No. 2), and WO 97/13877 (Reference No. 7), the Acacia Biosciences Press Release (Reference No. 8), and the Glaser article (Reference No. 9).

**U.S. Pat. No. 5,569,588** ("Methods for Drug Screening") ("the '588 patent"), issued October 29, 1996, with a priority date of August 9, 1995, describes an expression profiling platform, the "genome reporter matrix," which is based upon the measurement of protein expression levels. The '588 patent further describes use of nucleic acid microarrays to measure transcript expression levels, making clear that the utility of comparing multidimensional expression data sets equally applies to protein expression data and transcript expression data.

The '588 patent speaks clearly to the usefulness of such expression analyses, particularly but not exclusively protein expression profiling, in drug development and toxicology, particularly pointing out that a protein's failure to change in expression level is a useful result. Thus, with emphasis added,

[The invention provides] methods and compositions for modeling the transcriptional responsiveness of an organism to a candidate drug. . . . [The final step of the method comprises] comparing reporter gene product signals for each cell before and after contacting the cell with the candidate drug to obtain a drug response profile which provides a model of the transcriptional responsiveness of said organism to the candidate drug. [abstract]

The present invention exploits the recent advances in genome science to provide for the rapid screening of large numbers of compounds against a systemic target comprising substantially all targets in a pathway [or] organism. [column 1]

The ensemble of reporting cells comprises as comprehensive a collection of transcription regulatory genetic elements as is conveniently available for the targeted organism so as to most accurately model the systemic transcriptional response. Suitable ensembles generally comprise thousands of individually reporting elements; preferred ensembles are substantially comprehensive, i.e. provide a transcriptional response diversity comparable to that of the target organism. Generally, a substantially comprehensive ensemble requires transcription regulatory genetic elements from at least a majority of the organism's genes, and preferably includes those of all or nearly all of the genes. We term such a substantially comprehensive ensemble a genome reporter matrix. [column 2]

Drugs often have side effects that are in part due to the lack of target specificity. . . . [A] genome reporter matrix reveals the spectrum of other genes in the genome also affected by the compound. In considering two different compounds both of which induce the ERG10 reporter, if one compound affects the expression of 5 other reporters and a second compound affects the expression of 50 other reports, the first compound is, a priori, more likely to have fewer side effects. [columns 2-3]

Furthermore, it is not necessary to know the identity of any of the responding genes. [column 3]

[A]ny new compound that induces the same response profile as [a] . . . dominant tubulin mutant would provide a candidate for a taxol-like pharmaceutical. [column 4]

The genome reporter matrix offers a simple solution to recognizing new specificities in combinatorial libraries. Specifically, pools of new compounds are tested as mixtures

across the matrix. If the pool has any new activity not present in the original lead compound, new genes are affected among the reporters. [column 4]

A sufficient number of different recombinant cells are included to provide an ensemble of transcriptional regulatory elements of said organism sufficient to model the transcriptional responsiveness of said organism to a drug. In a preferred embodiment, the matrix is substantially comprehensive for the selected regulatory elements, e.g. essentially all of the gene promoters of the targeted organism are included. [columns 6-7]

In a preferred embodiment, the basal response profiles are determined. . . . The resultant electrical output signals are stored in a computer memory as genome reporter output signal matrix data structure associating each output signal with the coordinates of the corresponding microtiter plate well and the stimulus or drug. This information is indexed against the matrix to form reference response profiles that are used to determine the response of each reporter to any milieu in which a stimulus may be provided. After establishing a basal response profile for the matrix, each cell is contacted with a candidate drug. The term drug is used loosely to refer to agents which can provoke a specific cellular response. . . . The drug induces a complex response pattern of repression, silence and induction across the matrix . . . . The response profile reflects the cell's transcriptional adjustments to maintain homeostasis in the presence of the drug. . . . After contacting the cells with the candidate drug, the reporter gene product signals from each of said cells is again measured to determine a stimulated response profile. The basal o[r] background response profile is then compared with . . . the stimulated response profile to identify the cellular response profile to the candidate drug. [columns 7-8]

In another embodiment of the invention, a matrix [i.e., array] of hybridization probes corresponding to a predetermined population of genes of the selected organism is used to specifically detect changes in gene transcription which result from exposing the selected organism or cells thereof to a candidate drug. In this embodiment, one or more cells derived from the organism is exposed to the candidate drug in vivo or ex vivo under conditions wherein the drug effects a change in gene transcription in the cell to maintain homeostasis. Thereafter, the gene transcripts, primarily mRNA, of the cell or cells is isolated . . . [and] then contacted with an ordered matrix [array] of hybridization probes, each probe being specific for a different one of the transcripts, under conditions where each of the transcripts hybridizes with a corresponding one of the probes to form hybridization pairs. The ordered matrix of probes provides, in aggregate, complements for an ensemble of genes of the organism sufficient to model the transcriptional responsiveness of the organism to a drug. . . . The matrix-wide signal profile of the drug-stimulated cells is then compared with a matrix-wide signal profile of negative control cells to obtain a specific drug response profile. [column 8]

The invention also provides means for computer-based qualitative analysis of candidate drugs and unknown compounds. A wide variety of reference response profiles may be generated and used in such analyses. [column 8]

Response profiles for an unknown stimulus (e.g. new chemicals, unknown compounds or unknown mixtures) may be analyzed by comparing the new stimulus response profiles with response profiles to known chemical stimuli. [column 9]

The response profile of a new chemical stimulus may also be compared to a known genetic response profile for target gene(s). [column 9]

The August 11, 1997 press release from the '588 patent's assignee, Acacia Biosciences (now part of Merck) (Reference No. 8), and the September 15, 1997 news report by Glaser, Strategies for Target Validation Streamline Evaluation of Leads, Genetic Engineering News (Reference No. 9), attest the commercial value of the methods and technology described and claimed in the '588 patent.

**WO 95/21944** ("Differentially expressed genes in healthy and diseased subjects"), published August 17, 1995, describes the use of nucleic acid microarrays in expression profiling analyses, emphasizing that *patterns* of expression can be used to distinguish healthy tissues from diseased tissues and that *patterns* of expression can additionally be used in drug development and toxicology studies, without knowledge of the biological function of the encoded gene product. In particular, and with emphasis added:

The present invention involves . . . methods for diagnosing diseases . . . characterized by the presence of [differentially expressed] . . . genes, despite the absence of knowledge about the gene or its function. The methods involve the use of a composition suitable for use in hybridization which consists of a solid surface on which is immobilized at pre-defined regions thereon a plurality of defined oligonucleotide/ polynucleotide sequences for hybridization. Each sequence comprises a fragment of an EST. . . Differences in hybridization patterns produced through use of this composition and the specified methods enable diagnosis of diseases based on differential expression of genes of unknown function . . . [abstract]

The method [of the present invention] involves producing and comparing hybridization patterns formed between samples of expressed mRNA or cDNA polynucleotide sequences . . . and a defined set of oligonucleotide/polynucleotide[] . . . immobilized on a support. Those defined [immobilized] oligonucleotide/polynucleotide sequences are representative of the total expressed genetic component of the cells, tissues, organs or

organism as defined by the collection of partial cDNA sequences (ESTs). [page 2]

The present invention meets the unfilled needs in the art by providing methods for the . . . use of gene fragments and genes, even those of unknown full length sequence and unknown function, which are differentially expressed in a healthy animal and in an animal having a specific disease or infection by use of ESTs derived from DNA libraries of healthy and/or diseased/infected animals. [page 4]

Yet another aspect of the invention is that it provides . . . a means for . . . monitoring the efficacy of disease treatment regimes including . . . toxicological effects thereof. [page 4]

It has been appreciated that one or more differentially identified EST or gene-specific oligonucleotide/polynucleotides define a pattern of differentially expressed genes diagnostic of a predisease, disease or infective state. A knowledge of the specific biological function of the EST is not required only that the EST[] identifies a gene or genes whose altered expression is associated reproducibly with the predisease, disease or infectious state. [page 4]

As used herein, the term 'disease' or 'disease state' refers to any condition which deviates from a normal or standardized healthy state in an organism of the same species in terms of differential expression of the organism's genes. . . [whether] of genetic or environmental origin, for example, an inherited disorder such as certain breast cancers. . . .[or] administration of a drug or exposure of the animal to another agent, e.g., nutrition, which affects gene expression. [page 5]

As used herein, the term 'solid support' refers to any known substrate which is useful for the immobilization of large numbers of oligonucleotide/polynucleotide sequences by any available method . . . [and includes, *inter alia*,] nitrocellulose, . . . glass, silica. . . . [page 6]

By 'EST' or 'Expressed Sequence Tag' is meant a partial DNA or cDNA sequence of about 150 to 500, more preferably about 300, sequential nucleotides. . . . [page 6]

One or more libraries made from a single tissue type typically provide at least about 3000 different (i.e., unique) ESTs and potentially the full complement of all possible ESTs representing all cDNAs e.g., 50,000 – 100,000 in an animal such as a human. [page 7]

The lengths of the defined oligonucleotide/ polynucleotides may be readily increased or decreased as desired or needed. . . . The length is generally guided by the principle that it should be of sufficient length to insure that it is on[] average only represented once in the population to be examined. [page 7]

Comparing the . . . hybridization patterns permits detection of those defined oligonucleotide/ polynucleotides which are differentially expressed between the healthy control and the disease sample by the presence of differences in the hybridization patterns at pre-defined regions [of the solid support]. [page 13]

It should be appreciated that one does not have to be restricted in using ESTs from a particular tissue from which probe RNA or cDNA is obtained[;] rather any or all ESTs (known or unknown) may be placed on the support. Hybridization will be used [to] form diagnostic patterns or to identify which particular EST is detected. For example, all known ESTs from an organism are used to produce a 'master' solid support to which control sample and disease samples are alternately hybridized. [page 14]

Diagnosis is accomplished by comparing the two hybridization patterns, wherein substantial differences between the first and second hybridization patterns indicate the presence of the selected disease or infection in the animal being tested. Substantially similar first and second hybridization patterns indicate the absence of disease or infection. This[,] like many of the foregoing embodiments[,] may use known or unknown ESTs derived from many libraries. [page 18]

Still another intriguing use of this method is in the area of monitoring the effects of drugs on gene expression, both in laboratories and during clinical trials with animal[s], especially humans. [page 18]

WO 95/20681 ("Comparative Gene Transcript Analysis"), filed in 1994 by Applicants' assignee and published August 3, 1995, has three issued U.S. counterparts: U.S. Pat. Nos. 5,840,484, issued November 24, 1998; 6,114,114, issued September 5, 2000; and 6,303,297, issued October 16, 2001.

The specification describes the use of transcript expression *patterns*, or "images," each comprising multiple pixels of gene-specific information, for diagnosis, for cellular phenotyping, and in toxicology and drug development efforts. The specification describes a plurality of methods for obtaining the requisite expression data -- one of which is microarray hybridization -- and equates the uses of the expression data from these disparate platforms. In particular, and with emphasis added:

[The invention provides a] method and system for quantifying the relative abundance of gene transcripts in a biological specimen. . . . [G]ene transcript imaging can be used to detect or diagnose a particular biological state, disease, or condition which is correlated to the relative abundance of gene transcripts in a given cell or population of cells. The invention provides a method for comparing the gene transcript image analysis from two or more different biological specimens in order to distinguish between the two

specimens and identify one or more genes which are differentially expressed between the two specimens. [abstract]

[W]e see each individual gene product as a 'pixel' of information, which relates to the expression of that, and only that, gene. We teach herein [] methods whereby the individual 'pixels' of gene expression information can be combined into a single gene transcript 'image.' in which each of the individual genes can be visualized simultaneously and allowing relationships between the gene pixels to be easily visualized and understood. [page 2]

The present invention avoids the drawbacks of the prior art by providing a method to quantify the relative abundance of multiple gene transcripts in a given biological specimen. . . . The method of the instant invention provides for detailed diagnostic comparisons of cell profiles revealing numerous changes in the expression of individual transcripts. [page 6]

High resolution analysis of gene expression be used directly as a diagnostic profile. . . . [page 7]

The method is particularly powerful when more than 100 and preferably more than 1,000 gene transcripts are analyzed. [page 7]

The invention . . . includes a method of comparing specimens containing gene transcripts. [page 7]

The final data values from the first specimen and the further identified sequence values from the second specimen are processed to generate ratios of transcript sequences, which indicate the differences in the number of gene transcripts between the two specimens. [i.e., the results yield analogous data to microarrays] [page 8]

Also disclosed is a method of producing a gene transcript image analysis by first obtaining a mixture of mRNA, from which cDNA copies are made. [page 8]

In a further embodiment, the relative abundance of the gene transcripts in one cell type or tissue is compared with the relative abundance of gene transcript numbers in a second cell type or tissue in order to identify the differences and similarities. [page 9]

In essence, the invention is a method and system for quantifying the relative abundance of gene transcripts in a biological specimen. The invention provides a method for comparing the gene transcript image from two or more different biological specimens in order to distinguish between the two specimens. . . . [page 9]

[T]wo or more gene transcript images can be compared and used to detect or diagnose

a particular biological state, disease, or condition which is correlated to the relative abundance of gene transcripts in a given cell or population of cells. [pages 9-10]

The present invention provides a method to compare the relative abundance of gene transcripts in different biological specimens. . . . This process is denoted herein as gene transcript imaging. The quantitative analysis of the relative abundance for a set of gene transcripts is denoted herein as “gene transcript image analysis” or “gene transcript frequency analysis”. The present invention allows one to obtain a profile for gene transcription in any given population of cells or tissue from any type of organism. [page 11]

The invention has significant advantages in the fields of diagnostics, toxicology and pharmacology, to name a few. [page 12]

[G]ene transcript sequence abundances are compared against reference database sequence abundances including normal data sets for diseased and healthy patients. The patient has the disease(s) with which the patient’s data set most closely correlates. [page 12]

For example, gene transcript frequency analysis can be used to differentiate normal cells or tissues from diseased cells or tissues. . . . [page 12]

In toxicology, . . . [g]ene transcript imaging provides highly detailed information on the cell and tissue environment, some of which would not be obvious in conventional, less detailed screening methods. The gene transcript image is a more powerful method to predict drug toxicity and efficacy. Similar benefits accrue in the use of this tool in pharmacology. . . . [page 12]

In an alternative embodiment, comparative gene transcript frequency analysis is used to differentiate between cancer cells which respond to anti-cancer agents and those which do not respond. [page 12]

In a further embodiment, comparative gene transcript frequency analysis is used . . . for the selection of better pharmacologic animal models. [page 14]

In a further embodiment, comparative gene transcript frequency analysis is used in a clinical setting to give a highly detailed gene transcript profile of a diseased state or condition. [page 14]

An alternate method of producing a gene transcript image includes the steps of obtaining a mixture of test mRNA and providing a representative array of unique probes whose sequences are complementary to at least some of the test mRNAs. Next, a fixed amount of the test mRNA is added to the arrayed probes. The test

mRNA is incubated with the probes for a sufficient time to allow hybrids of the test mRNA and probes to form. The mRNA-probe hybrids are detected and the quantity determined. [page 15]

[T]his research tool provides a way to get new drugs to the public faster and more economically. [page 36]

In this method, the particular physiologic function of the protein transcript need not be determined to qualify the gene transcript as a clinical marker. [page 38]

[T]he gene transcript changes noted in the earlier rat toxicity study are carefully evaluated as clinical markers in the followed patients. Changes in the gene transcript image analyses are evaluated as indicators of toxicity by correlation with clinical signs and symptoms and other laboratory results. . . . The . . . analysis highlights any toxicological changes in the treated patients. [page 39]

WO 97/13877 (“Measurement of Gene Expression Profiles in Toxicity Determinations”), filed on October 11, 1996 and published on April 17, 1997 (shortly after the April 8, 1997 filing date of the parent application for the instant U.S. Serial No. 09/203,545 application), describes an expression profiling technology differing somewhat from the use of cDNA microarrays and differing from the genome reporter matrix of the ‘588 patent; but the use of the data is analogous. As per its title, the WO 97/13877 publication describes use of expression profiling in toxicity determinations. In particular, and with emphasis added:

[T]he invention relates to a method for detecting and monitoring changes in gene expression patterns in in vitro and in vivo systems for determining the toxicity of drug candidates. [Field of the invention]

An object of the invention is to provide a new approach to toxicity assessment based on an examination of gene expression patterns, or profiles, in in vitro or in vivo test systems. [page 3]

Another object of the invention is to provide a rapid and reliable method for correlating gene expression with short term and long term toxicity in test animals. [page 3]

The invention achieves these and other objects by providing a method for massively parallel signature sequencing of genes expressed in one or more selected tissues of an organism exposed to a test compound. An important feature of the invention is the application of novel . . . methodologies that permit the formation of gene expression profiles for selected tissues. . . . Such profiles may be compared with those from tissues

of control organisms at single or multiple time points to identify expression patterns predictive of toxicity. [page 3]

As used herein, the terms “gene expression profile,” and “gene expression pattern” which is used equivalently, means a frequency distribution of sequences of portions of cDNA molecules sampled from a population of tag-cDNA conjugates . . . Preferably, the total number of sequences determined is at least 1000; more preferably, the total number of sequences determined in a gene expression profile is at least ten thousand. [page 7]

The invention provides a method for determining the toxicity of a compound by analyzing changes in the gene expression profiles in selected tissues of test organisms exposed to the compound . . . Gene expression profiles derived from test organisms are compared to gene expression profiles derived from control organisms. . . . [page 7]

In fact, the potential benefit to the public of having the claimed expressed polypeptide, in terms of lives saved and reduced health care costs, are enormous. Evidence of the benefits of this information include the following:

- In 1999, CV Therapeutics, an Incyte collaborator, was able to use Incyte gene expression technology, information about the structure of a known transporter gene, and chromosomal mapping location, to identify the key gene associated with Tangier disease. This discovery took place over a matter of only a few weeks, due to the power of these new genomics technologies. The discovery received an award from the American Heart Association as one of the top 10 discoveries associated with heart disease research in 1999.
- In an April 9, 2000, article published by the Bloomberg news service, an Incyte customer stated that it had reduced the time associated with target discovery and validation from 36 months to 18 months, through use of Incyte's genomic information database. Other Incyte customers have privately reported similar experiences. The implications of this significant saving of time and expense for the number of drugs that may be developed and their cost are obvious.
- In a February 10, 2000, article in the *Wall Street Journal*, one Incyte customer stated that over 50 percent of the drug targets in its current pipeline were derived from the Incyte database. Other Incyte customers have privately reported similar experiences. By doubling the number of targets available to pharmaceutical researchers, Incyte genomic information has demonstrably accelerated the development of new drugs.

Because the Patent Examiner failed to address or consider the “well-established” utilities for the claimed invention in toxicology testing, drug development, and the diagnosis of disease, the Examiner’s rejections should be overturned regardless of their merit.

**E. Objective evidence corroborates the utilities of the claimed invention**

There is in fact no restriction on the kinds of evidence a Patent Examiner may consider in determining whether a “real-world” utility exists. “Real-world” evidence, such as evidence showing actual use or commercial success of the invention, can demonstrate conclusive proof of utility.

*Raytheon v. Roper*, 220 USPQ2d 592 (Fed. Cir. 1983); *Nestle v. Eugene*, 55 F.2d 854, 856, 12 USPQ 335 (6th Cir. 1932). Indeed, proof that the invention is made, used or sold by any person or entity other than the patentee is conclusive proof of utility. *United States Steel Corp. v. Phillips Petroleum Co.*, 865 F.2d 1247, 1252, 9 USPQ2d 1461 (Fed. Cir. 1989).

Over the past several years, a vibrant market has developed for databases containing the sequences of all expressed genes (along with the polypeptide translations of those genes), in particular genes having medical and pharmaceutical significance such as the instant sequence. (Note that the value in these databases is enhanced by their completeness, but each sequence in them is independently valuable.) The databases sold by Applicants’ assignee, Incyte, include exactly the kinds of information made possible by the claimed invention, such as tissue and disease associations. Incyte sells its database containing the sequence of the claimed polypeptide and millions of other sequences throughout the scientific community, including to pharmaceutical companies who use the information to develop new pharmaceuticals.

Both Incyte’s customers and the scientific community have acknowledged that Incyte’s databases have proven to be valuable in, for example, the identification and development of drug candidates. For example, Page et al., in discussing the identification and assignment of candidate targets, states that “rapid identification and assignment of candidate targets and markers represents a huge challenge . . . [t]he process of annotation is similarly aided by the quality and richness of the sequence specific databases that are currently available, both in the public domain and in the private sector (e.g. those supplied by Incyte Pharmaceuticals)” (Page, M.J., Amess, B., Rohlf, C.,

Stubberfield, C., Parekh, R., Proteomics: a major new technology for the drug discovery process, Drug Discov. Today 4:55-62 (1999), Reference No. 22, enclosed, see page 58, col. 2). As Incyte adds information to its databases, including the information that can be generated only as a result of Incyte's discovery of the claimed polypeptide, the databases become even more powerful tools. Thus, the claimed invention adds more than incremental benefit to the drug discovery and development process.

Customers can, moreover, purchase polynucleotides encoding the claimed polypeptide directly from Incyte, saving the customer the time and expense of isolating and purifying or cloning the polynucleotide for research uses such as those described *supra*.

### **III. The Patent Examiner's Rejections Are Without Merit**

The Examiner fails to recognize that the disclosed and well-established utilities for the claimed polypeptide are specific and/or substantial asserted utilities and well established utilities. (Office Action of 12/31/03 at page 3). The Examiner is incorrect both as a matter of law and as a matter of fact.

#### **A. The Precise Biological Role Or Function of An Expressed Polypeptide Is Not Required to Demonstrate Utility**

One of the Examiner's grounds of rejection of the claimed invention is based on the ground that, without information as to "any particular function or biological significance" of the claimed invention, the claimed invention's utility is not sufficiently specific or substantial. According to the Examiner, a potential function based on amino acid sequence similarity to other known proteins does not, without further research, support a conclusion that IGFAM-6 of the instant application was, as of the filing date, useful. The Examiner would require, in addition, that the applicant provide experimental results characterizing the claimed compounds such that a specific and substantial interpretation of the results generated in any given experiment would provide some actual and specific significance attributable to the IGFAM-6 protein.

It may be that specific and substantial interpretations and detailed information on biological function are necessary to satisfy the requirements for publication in some technical journals, but they are not necessary to satisfy the requirements for obtaining a United States patent. The relevant question is

not, as the Examiner would have it, whether it is known how or why the invention works, *In re Cortwright*, 165 F.3d 1353, 1359 (Fed. Cir. 1999), but rather whether the invention provides an “identifiable benefit” in presently available form. *Juicy Whip Inc. v. Orange Bang Inc.*, 185 F.3d 1364, 1366 (Fed. Cir. 1999). If the benefit exists, and there is a substantial likelihood the invention provides the benefit, it is useful. There can be no doubt, particularly in view of the Rockett Declaration (at, e.g., ¶¶ 10-18), the Bedilion Declaration (at, e.g., ¶¶ 4-7), and the Iyer Declaration (at, e.g., ¶¶ 5-10), that the present invention meets this test.

The threshold for determining whether an invention produces an identifiable benefit is low. *Juicy Whip*, 185 F.3d at 1366. Only those utilities that are so nebulous that a person of ordinary skill in the art would not know how to achieve an identifiable benefit and, at least according to the PTO guidelines, so-called “throwaway” utilities that are not directed to a person of ordinary skill in the art at all, do not meet the statutory requirement of utility. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001).

Knowledge of the biological function or role of a biological molecule has never been required to show real-world benefit. In its most recent explanation of its own utility guidelines, the PTO acknowledged as much (66 F.R. at 1095):

[T]he utility of a claimed DNA does not necessarily depend on the function of the encoded gene product. A claimed DNA may have specific and substantial utility because, e.g., it hybridizes near a disease-associated gene or it has gene-regulating activity.

By implicitly requiring knowledge of biological function for any claimed polypeptide, the Examiner has, contrary to law, elevated what is at most an evidentiary factor into an absolute requirement of utility. Rather than looking to the biological role or function of the claimed invention, the Examiner should have looked first to the benefits it is alleged to provide.

## **B. Membership in a Class of Useful Products Can Be Proof of Utility**

Despite the uncontradicted evidence that the claimed polypeptide is a member of the immunoglobulin superfamily of proteins, whose members indisputably are useful, the Examiner refused to impute the utility of the members of the immunoglobulin superfamily of proteins to IGFAM-6. In the

Office Action of 12/31/03, the Patent Examiner takes the position that “[i]t is not clear if the protein of the instant application would have the same function in mediating adhesive interactions at the synaptic junction or transmigration of monocytes across endothelial cells” (Office Action of 12/31/03, page 4), and also without knowing which particular biological function within the class of immunoglobulin superfamily proteins is possessed by IGFAM-6, utility cannot be imputed. To demonstrate utility by membership in the class of immunoglobulin superfamily proteins, the Examiner would require that all immunoglobulin superfamily proteins possess a “common” utility.

There is no such requirement in the law. In order to demonstrate utility by membership in a class, the law requires only that the class not contain a substantial number of useless members. So long as the class does not contain a substantial number of useless members, there is sufficient likelihood that the claimed invention will have utility, and a rejection under 35 U.S.C. § 101 is improper. That is true regardless of how the claimed invention ultimately is used and whether the members of the class possess one utility or many. *See Brenner v. Manson*, 383 U.S. 519, 532 (1966); *Application of Kirk*, 376 F.2d 936, 943 (CCPA 1967).

Membership in a “general” class is insufficient to demonstrate utility only if the class contains a substantial number of useless members. There would be, in that case, a substantial likelihood that the claimed invention is one of the useless members of the class. In the few cases in which class membership did not prove utility by substantial likelihood, the classes did in fact include predominately useless members. *E.g.*, *Brenner* (man-made steroids); *Kirk* (same); *Natta* (man-made polyethylene polymers).<sup>2</sup>

The Examiner addresses IGFAM-6 as if the general class in which it is included is not the immunoglobulin superfamily protein family, but rather all polypeptides, including the vast majority of useless theoretical molecules not occurring in nature, and thus not pre-selected by nature to be useful. While these “general classes” may contain a substantial number of useless members, the immunoglobulin superfamily protein family does not. The immunoglobulin superfamily protein family is sufficiently

---

<sup>2</sup>At a Biotechnology Customer Partnership Meeting held at the USPTO on April 17, 2001, PTO Senior Examiner James Martinell described an analytical framework roughly consistent with this analysis. He stated that when an applicant’s claimed protein “is a member of a family of proteins that already are known based upon sequence homology,” that can be an effective assertion of utility.

specific to rule out any reasonable possibility that IGFAM-6 would not also be useful like the other members of the family.

Because the Examiner has not presented any evidence that the immunoglobulin superfamily class of proteins has any, let alone a substantial number, of useless members, the Examiner must conclude that there is a “substantial likelihood” that the IGFAM-6 encoded by the claimed polypeptide is useful.

Even if the Examiner’s “common utility” criterion were correct – and it is not – the immunoglobulin superfamily protein family would meet it. It is undisputed that JAM proteins are known members of the immunoglobulin superfamily of proteins which play a structural role in the control of monocyte migration across epithelium or endothelium to sites of inflammation (see Specification, page 4, lines 9-19). A person of ordinary skill in the art need not know any more about how the claimed invention plays a structural role in the control of monocyte migration across epithelium or endothelium to sites of inflammation to use it, and the Examiner presents no evidence to the contrary. Instead, the Examiner makes the conclusory observation that a person of ordinary skill in the art would need to know whether, for example, any given immunoglobulin superfamily protein plays a structural role in the control of monocyte migration across epithelium or endothelium to sites of inflammation (see Specification, page 4, lines 9-19). The Examiner then goes on to assume that the only use for IGFAM-6 absent knowledge as to how this member of the immunoglobulin superfamily protein family actually works is further study of IGFAM-6 itself.

As demonstrated by Applicants, knowledge that IGFAM-6 is an immunoglobulin superfamily protein, specifically a homolog of murine JAM, is more than sufficient to make it useful for the diagnosis and treatment of cancer, immune system disorders, and infections. Indeed, the polynucleotide encoding IGFAM-6 has been shown to be expressed in cancer, immune system disorders, and infections (see Specification, page 64, Table 3, column 4). The Examiner must accept these facts to be true unless the Examiner can provide evidence or sound scientific reasoning to the contrary. But the Examiner has not done so.

**C. The uses of IGFAM-6 in toxicology testing, drug discovery, and disease diagnosis are practical uses beyond mere study of the invention itself**

The Examiner rejected the claims at issue on the ground that the use of an invention as tool for research is not a “substantial” use. Because the Examiner’s rejection assumes a substantial overstatement of the law, and is incorrect in fact, it must be overturned.

There is no authority for the proposition that use as a tool for research is not a substantial utility. Indeed, the Patent Office itself has recognized that just because an invention is used in a research setting does not mean that it lacks utility (Section 2107.01 of the Manual of Patent Examining Procedure, 8<sup>th</sup> Edition, February 2003 revision, under the heading I. Specific and Substantial Requirements, Research Tools):

Many research tools such as gas chromatographs, screening assays, and nucleotide sequencing techniques have a clear, specific and unquestionable utility (e.g., they are useful in analyzing compounds). An assessment that focuses on whether an invention is useful only in a research setting thus does not address whether the specific invention is in fact “useful” in a patent sense. Instead, Office personnel must distinguish between inventions that have a specifically identified substantial utility and inventions whose asserted utility requires further research to identify or reasonably confirm.

The PTO’s actual practice has been, at least until the present, consistent with that approach. It has routinely issued patents for inventions whose only use is to facilitate research, such as DNA ligases, acknowledged by the PTO’s Training Materials to be useful.

The subset of research uses that are not “substantial” utilities is limited. It consists only of those uses in which the claimed invention is to be an **object** of further study, thus merely inviting further research on the invention itself. This follows from *Brenner*, in which the U.S. Supreme Court held that a process for making a compound does not confer a substantial benefit where the only known use of the compound was to be the object of further research to determine its use. *Id.* at 535. Similarly, in *Kirk*, the Court held that a compound would not confer substantial benefit on the public merely because it might be used to synthesize some other, unknown compound that would confer substantial benefit. *Kirk*, 376 F.2d at 940, 945. (“What appellants are really saying to those in the art is take these steroids, experiment, and find what use they do have as medicines.”) Nowhere do those cases state or imply, however, that a material cannot be patentable if it has some other, additional beneficial use in research.

Such beneficial uses beyond studying the claimed invention itself have been demonstrated, in

particular those described in the Rockett Declaration, the Bedilion Declaration, and the Iyer Declaration. The Rockett Declaration, the Bedilion Declaration, and the Iyer Declaration demonstrate that the claimed invention is a tool, rather than an object, of research, and it demonstrates exactly how that tool is used. Without the claimed invention, it would be more difficult to generate information regarding the properties of tissues, cells, drug candidates and toxins apart from additional information about the polypeptide itself.

As used in toxicology testing, drug discovery, and disease diagnosis, the claimed invention has a beneficial use in research other than studying the claimed invention or its protein products. It is a tool, rather than an object, of research. The data generated in gene and protein expression monitoring using the claimed invention as a tool is **not** used merely to study the claimed polypeptide itself, but rather to study properties of tissues, cells, and potential drug candidates and toxins. Without the claimed invention, the information regarding the properties of tissues, cells, drug candidates and toxins is less complete (e.g., Rockett Declaration at ¶¶ 10-18 and Iyer Declaration at ¶¶ 3-9).

The use of the claimed invention as a research tool in toxicology testing is specific and substantial. While it is true that all polypeptides and polynucleotides expressed in humans have utility in toxicology testing based on the property of being expressed at some time in development or in the cell life cycle, this basis for utility does not preclude that utility from being specific and substantial. A toxicology test using any particular expressed polypeptide or polynucleotide is dependent on the identity of that polypeptide or polynucleotide, not on its biological function or its disease association. The results obtained from using any particular human-expressed polypeptide or polynucleotide in toxicology testing is specific to both the compound being tested and the polypeptide polynucleotide used in the test. No two human-expressed polypeptides or polynucleotides are interchangeable for toxicology testing because the effects on the expression of any two such polypeptides or polynucleotides will differ depending on the identity of the compound tested and the identities of the two polypeptides or polynucleotides. It is not necessary to know the biological functions and disease associations of the polypeptides or polynucleotides in order to carry out such toxicology tests. Therefore, at the very least, the claimed polypeptides or polynucleotides are specific controls for toxicology tests in developing drugs targeted to other polypeptides or polynucleotides, and are clearly useful as such.

As an example, any histone gene or protein expressed in humans can be used in a specific and substantial toxicology test in drug development. A histone gene or protein may not be suitable as a target for drug development because disruption of such a gene may kill a patient. However, a human-expressed histone gene or protein is surely an excellent subject for toxicology studies when developing drugs targeted to other genes or proteins. A drug candidate which alters expression of a histone gene or protein is toxic because disruption of such a pervasively-expressed gene or protein would have undesirable side effects in a patient. Therefore, when testing the toxicology of a drug candidate targeted to another gene or protein, measuring the expression of a histone gene or protein is a good measure of the toxicity of that candidate, particularly in *in vitro* cellular assays at an early stage of drug development. The utility of any particular human-expressed histone gene or protein in toxicology testing is specific and substantial because a toxicology test using that histone gene or protein cannot be replaced by a toxicology test using a different gene, including any other histone gene or protein. This specific and substantial utility requires no knowledge of the biological function or disease association of the histone gene or protein.

The expression of SEQ ID NO:6 in human tissues would lead a skilled artisan to believe that this polypeptide has some physiological implications, even if these implications have not been precisely identified. During toxicology testing, a change in expression of a human-expressed polypeptide indicates potential toxicity of a drug candidate, even if the physiological implications of that polypeptide are unknown. Such a toxicology test allows one to choose a lead drug candidate which has minimal effects on the expression of proteins other than the protein to which the candidate is targeted. Such a lead drug candidate would be less likely to have unintended side effects than a drug candidate having greater effects on the expression of genes/proteins other than the intended drug target. Thus, the benefit of such a toxicology test is an increased chance of finding a safe and effective drug, and a corresponding reduction in the expense and time of bringing a drug to market.

The claimed invention has numerous other uses as a research tool, each of which alone is a “substantial utility.” These include: a fragment of SEQ ID NO:6 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:6 (see Specification, page 12, lines 30-31; page 21, lines 25-26) and screening libraries of compounds in a variety of drug screening techniques (see Specification, page 44, lines 21-25).

**D. The Patent Examiner Failed to Demonstrate That a Person of Ordinary Skill in the Art Would Reasonably Doubt the Utility of the Claimed Invention**

Based principally on citations to scientific literature identifying some of the difficulties involved in predicting protein function, the Examiner rejected the pending claims on the ground that the applicant cannot impute utility to the claimed invention based on its homology to another polypeptide undisputed by the Examiner to be useful. The Examiner's rejection is both incorrect as a matter of fact and as a matter of procedural law.

As demonstrated in § II.A., *supra*, the literature cited by the Examiner is not inconsistent with the Applicants' proof of homology by a reasonable probability. It may show that Applicants cannot prove function by homology with **certainty**, but Applicants need not meet such a rigorous standard of proof. Under the applicable law, once the applicant demonstrates a *prima facie* case of homology, the Examiner must accept the assertion of utility to be true unless the Examiner comes forward with evidence showing a person of ordinary skill would doubt the asserted utility could be achieved by a reasonable probability. *See In re Brana*, 51 F.3d at 1566; *In re Langer*, 503 F.2d 1380, 1391-92, 183 USPQ 288 (CCPA 1974). The Examiner has not made such a showing and, as such, the Examiner's rejection should be overturned.

**1. Applicants' Showing of Facts Overcomes The Examiner's Concern That Applicants' Invention Lacks "Specific Utility"**

The Examiner alleges that "the specification fails to disclose any particular function or biological significance for (IGFAM). . . . After further research, specific and substantial credible utility might be found for the claimed isolated compositions. This further characterization, however, is part of the act of invention and until it has been undertaken, Applicants claimed invention is incomplete." (Office Action of 12/31/03, page 3).

Applicants' submission of the Rockett Declaration (e.g., ¶¶ 11-18) overcomes this concern. The Rockett Declaration demonstrates that, far from applying **regardless** of the specific properties of the claimed invention, the utility of Applicants' claimed polypeptide **depends upon** properties -- its amino acid sequence-- that allow it specifically to be identified, for example, by specific antibodies or

by 2-D PAGE and mass spectroscopy sequencing of spots on the gel.

Although not required for present purposes, it would be appropriate to state on the record here that the specificity of protein-antibody binding was well-established in the art far earlier than the development of antibody microarrays in the 1980s, and indeed is the well-established underpinning of many, perhaps most, immunoassay techniques over the past several decades.

**IV. By Requiring the Patent Applicant to Assert a Particular or Unique Utility, the Patent Examination Utility Guidelines and Training Materials Applied by the Patent Examiner Misstate the Law**

There is an additional, independent reason to overturn the rejections: to the extent the rejections are based on Revised Interim Utility Examination Guidelines (64 FR 71427, December 21, 1999), the final Utility Examination Guidelines (66 FR 1092, January 5, 2001) and/or the Revised Interim Utility Guidelines Training Materials (USPTO Website [www.uspto.gov](http://www.uspto.gov), March 1, 2000), the Guidelines and Training Materials are themselves inconsistent with the law.

The Training Materials, which direct the Examiners regarding how to apply the Utility Guidelines, address the issue of specificity with reference to two kinds of asserted utilities: “specific” utilities, which meet the statutory requirements, and “general” utilities, which do not. The Training Materials define a “specific utility” as follows:

A [specific utility] is *specific* to the subject matter claimed. This contrasts to *general* utility that would be applicable to the broad class of invention. For example, a claim to a polynucleotide whose use is disclosed simply as “gene probe” or “chromosome marker” would not be considered to be specific in the absence of a disclosure of a specific DNA target. Similarly, a general statement of diagnostic utility, such as diagnosing an unspecified disease, would ordinarily be insufficient absent a disclosure of what condition can be diagnosed.

The Training Materials distinguish between “specific” and “general” utilities by assessing whether the asserted utility is sufficiently “particular,” *i.e.*, unique (Training Materials at p.52) as compared to the “broad class of invention.” (In this regard, the Training Materials appear to parallel the view set forth in Stephen G. Kunin, Written Description Guidelines and Utility Guidelines, 82

J.P.T.O.S. 77, 97 (Feb. 2000) (“With regard to the issue of specific utility the question to ask is whether or not a utility set forth in the specification is *particular* to the claimed invention.”).)

Such “unique” or “particular” utilities never have been required by the law. To meet the utility requirement, the invention need only be “practically useful,” *Natta*, 480 F.2d 1 at 1397, and confer a “specific benefit” on the public. *Brenner*, 383 U.S. at 534. Thus incredible “throwaway” utilities, such as trying to “patent a transgenic mouse by saying it makes great snake food,” do not meet this standard. Karen Hall, Genomic Warfare, *The American Lawyer* 68 (June 2000) (quoting John Doll, Chief of the Biotech Section of USPTO).

This does not preclude, however, a general utility, contrary to the statement in the Training Materials where “specific utility” is defined (page 5). Practical real-world uses are not limited to uses that are unique to an invention. The law requires that the practical utility be “definite,” not particular. *Montedison*, 664 F.2d at 375. Applicants are not aware of any court that has rejected an assertion of utility on the grounds that it is not “particular” or “unique” to the specific invention. Where courts have found utility to be too “general,” it has been in those cases in which the asserted utility in the patent disclosure was not a practical use that conferred a specific benefit. That is, a person of ordinary skill in the art would have been left to guess as to how to benefit at all from the invention. In *Kirk*, for example, the CCPA held the assertion that a man-made steroid had “useful biological activity” was insufficient where there was no information in the specification as to how that biological activity could be practically used. *Kirk*, 376 F.2d at 941.

The fact that an invention can have a particular use does not provide a basis for requiring a particular use. *See Brana, supra* (disclosure describing a claimed antitumor compound as being homologous to an antitumor compound having activity against a “particular” type of cancer was determined to satisfy the specificity requirement). “Particularity” is not and never has been the *sine qua non* of utility; it is, at most, one of many factors to be considered.

As described *supra*, broad classes of inventions can satisfy the utility requirement so long as a person of ordinary skill in the art would understand how to achieve a practical benefit from knowledge of the class. Only classes that encompass a significant portion of non useful members would fail to meet the utility requirement. *Supra* §III.B. (*Montedison*, 664 F.2d at 374-75).

The Training Materials fail to distinguish between broad classes that convey information of

practical utility and those that do not, lumping all of them into the latter, unpatentable category of “general” utilities. As a result, the Training Materials paint with too broad a brush. Rigorously applied, they would render unpatentable whole categories of inventions heretofore considered to be patentable, and that have indisputably benefitted the public, including the claimed invention. *See supra* § III.B. Thus, the Training Materials cannot be applied consistently with the law.

**V. To the extent the rejection of the claimed invention under 35 U.S.C. § 112, first paragraph, is based on the improper rejection for lack of utility under 35 U.S.C. § 101, it must be withdrawn.**

The rejection set forth in the Office Action is based on the assertions discussed above, i.e., that the claimed invention lacks patentable utility. To the extent that the rejection under 35 U.S.C. § 112, first paragraph, is based on the improper allegation of lack of patentable utility under 35 U.S.C. § 101, it fails for the same reasons.

**VI. Summary**

Applicants request that the rejections of the claims be withdrawn for at least the above reasons.

Applicants respectfully submit that rejections for lack of utility based, *inter alia*, on an allegation of “lack of specificity,” as set forth in the Office Action and as justified in the Revised Interim and final Utility Guidelines and Training Materials, are not supported in the law. Neither are they scientifically correct, nor supported by any evidence or sound scientific reasoning. These rejections are alleged to be founded on facts in court cases such as *Brenner* and *Kirk*, yet those facts are clearly distinguishable from the facts of the instant application, and indeed most if not all nucleotide and protein sequence applications. Nevertheless, the PTO is attempting to mold the facts and holdings of these prior cases, “like a nose of wax,”<sup>3</sup> to target rejections of claims to polypeptides and polynucleotides where biological activity information has not been proven by laboratory experimentation, and they have

---

<sup>3</sup>“The concept of patentable subject matter under §101 is not ‘like a nose of wax which may be turned and twisted in any direction \* \* \*.’ *White v. Dunbar*, 119 U.S. 47, 51.” (*Parker v. Flook*, 198 USPQ 193 (US SupCt 1978))

done so by ignoring perfectly acceptable utilities fully disclosed in the specifications as well as well-established utilities known to those of skill in the art. As is disclosed in the specification, and even more clearly, as one of ordinary skill in the art would understand, the claimed invention has well-established, specific, substantial and credible utilities. The rejections are, therefore, improper and should be withdrawn.

Moreover, to the extent the above rejections were based on the Revised Interim and final Examination Guidelines and Training Materials, those portions of the Guidelines and Training Materials that form the basis for the rejections should be determined to be inconsistent with the law.

**Rejection under 35 U.S.C. 112, first paragraph, Enablement**

Claims 21-22, 24, and 32-33 stand rejected under 35 U.S.C. § 112, first paragraph based on the allegation that the Specification does not “enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.” In particular, the Examiner asserts that the Specification “fails to provide any guidance as to how to make (a) any polypeptide comprising a “naturally occurring” amino acid sequence at least 90% identical to any amino acid sequence of SEQ ID NO:6, (b) any biologically active fragment of any polypeptide having any amino acid sequence of SEQ ID NO:6, and (c) any immunogenic fragment of any polypeptide having any amino acid sequence of SEQ ID NO:6 in claims 21-22 and 24; any composition comprising any polypeptide of and (b) or (c) mentioned above” (Office Action of 12/19/03, page 5). Such, however, is not the case.

The Specification discloses methods to make a polypeptide having any particular amino acid sequence (e.g., at page 25, lines 9-19). Given the information provided by SEQ ID NO:6 (the amino acid sequence of IGFAM-6), one of skill in the art would be able to routinely obtain a “naturally occurring” amino acid sequence at least 90% identical to any amino acid sequence of SEQ ID NO:6 including biologically active and immunogenic fragments of SEQ ID NO:6.

**I. The Legal Standard**

The legal standard for enablement is a well-settled issue. For example, in *Hybritech*

*Incorporated v. Monoclonal Antibodies, Inc.*, 231 USPQ 81 (CAFC 1986), the court stated that:

Enablement is a legal determination of whether a patent enables one skilled in the art to make and use the claimed invention, *Raytheon Co. v. Roper Corp.*, 724 F.2d 951, 960, 220 USPQ 592, 599 (Fed. Cir. 1983), is not precluded even if some experimentation is necessary, although the amount of experimentation needed must not be unduly extensive . . . a patent need not teach, and preferably omits, what is well known in the art. *Lindemann*, 730 F.2d at 1463, 221 USPQ at 489.

The Specification discloses how to make the polypeptides of SEQ ID NO:6, variants, and biologically active and immunogenic fragments thereof.

## **II. The Specification Has Enabled the Claimed Polypeptide Commensurate in Scope with the Claims**

Applicants maintain that the specification fully enables the making and using of the claimed polypeptides commensurate in scope with the claims.

### **A. Making the Polypeptides**

The Specification fully enables the making of the SEQ ID NO:6 polypeptides. (See, e.g., Sequence Listing and Specification, page 25 line 6 through page 30, line 21.)

Applicants further submit that the Specification fully enables the making of the polypeptide variants. The polypeptide sequence of SEQ ID NO:6 is provided in the Sequence Listing. The Examiner stated that:

Other than the specific SEQ ID NO:6 mentioned above, the specification fails to provide any guidance as how to make (a) any polypeptide comprising any naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:6, (b) any biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:6, and (c) any immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:6; any composition comprising any polypeptide of (a), (b) or (c) mentioned above. (Office Action mailed 12/19/03, page 5.)

However, predictability of other “naturally-occurring” variant polypeptides is not needed in order to make such polypeptides. That is, the claims define the variant polypeptides as “naturally occurring” and being at least 90% identical to the amino acid sequence of SEQ ID NO:6. The

existence of such variants is made by nature; and “naturally occurring” polypeptide variants occur in nature. The Specification teaches how to find polynucleotide variants (See, e.g., page 40, lines 19-29) which can then be expressed to make polypeptide variants. The Specification also teaches how to use antibodies to purify naturally occurring IGFAM-6 (See, e.g., page 54, lines 24-34). The scope of the polypeptide variants is described by the phrase “at least 90% identical to the full length of the sequence of SEQ ID NO:6.” The Specification describes how to use BLAST to determine whether a given sequence falls within the “at least 90% identical” scope (See, e.g., page 14, line 28 through page 15, line 22; page 48, lines 6-31). In addition, determination of percentage identity is well known in the art. Moreover, the “comprising” language used to define the variant polypeptides does not preclude the ability to make the claimed subject matter. The term “comprising” as used in the Specification merely encompasses, for example, fusion proteins which contain the variant sequences (See, e.g., page 29, line 28 through page 30, line 11; page 52, lines 14-25). Methods for making fusion proteins are well known in the art.

**B. Making the Biologically Active Fragments of IGFAM-6**

Applicants submit that the Specification fully enables the making of the claimed biologically active fragments of the SEQ ID NO:6 polypeptide. The polypeptide sequence of SEQ ID NO:6 is provided in the Sequence Listing. Possible amino acids and polypeptide fragments of SEQ ID NO:6 which are biologically active are taught in the Specification on page 60, Table 2, columns 3-5. Preparation of biologically active fragments is described in the Specification, e.g., at page 25, lines 6-23. Determinations of biological activity of IGFAM-6 and biologically active fragments thereof are taught in the Specification, e.g., page 52, line 26 through page 53, line 11.

Applicants note that the instant Specification states that “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule.” (page 10 lines 18-19.) Prediction of biologically active fragments may be done using methods described in the Specification, such as the use of PROFILESCAN, BLIMPS, MOTIFS, and PFAM software programs as well as the algorithms taught in Table 5, pages 71-72.

The ability of a given fragment to interact with another molecule tests whether the fragment is “biologically active” (See, e.g., Example X, page 52, line 26 through page 53, line 11, Example XI,

page 53, line 12 through page 54, line 7, and page 55, lines 1-7). The tests of fragments by these methods are routine practices in the art and, hence, do not require undue experimentation (In re Wands (858 F.2d 731, 8 USPQ2d 1400) Fed. Cir. 1988); the Specification provides a test for IGFAM activity (See, e.g., at page 52, line 26 through page 53, line 11).

**C. Making the Immunogenic Fragments of IGFAM-6**

Applicants submit that the Specification fully enables the making of the claimed immunogenic fragments of the SEQ ID NO:6 polypeptide. The polypeptide sequence of SEQ ID NO:6 is provided in the Sequence Listing. Possible polynucleotide fragments of SEQ ID NO:25 which encode potential immunogenic fragments of SEQ ID NO:6 are taught in the Specification on page 64, Table 3, column 2. Preparation of immunogenic fragments is described in the Specification, e.g., at page 21, lines 22-26 and page 54, lines 8-23.

Applicants note that the instant Specification states that “immunologically active” refers to the capability of the natural, recombinant, or synthetic IGFAM, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.” (page 10 lines 19-21.) The terms “immunologically active” and “immunogenic” are interchangeable. Prediction of immunogenic fragments may be done using methods described in the Specification, such as the use of DNASTAR software, as well as choosing possible epitopes near the C-terminus or in hydrophilic regions, e.g., on page 54, lines 8-23.

The ability of a given fragment to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies are tests for whether the fragment is “immunogenic” (See, e.g., page 10 lines 19-21, page 12, lines 28-34, page 32, line 32 through page 33, line 11, and page 54, lines 8-23). The tests of fragments by these methods are routine practices in the art and, hence, do not require undue experimentation (In re Wands (858 F.2d 731, 8 USPQ2d 1400) Fed. Cir. 1988); the Specification provides a test for antibody binding (See, e.g., at page 34, lines 3-9).

Thus, the instant specification is enabling for the making and using the claimed polypeptides commensurate with the scope of the claims.

**III. The present claims do not define a genus which is “highly variant”**

The Examiner argues that the present claims encompass a broad genus of protein[s], i.e., subsequences. Additionally, the Examiner raises the concern that “changes up to 10% of an amino acid sequence does not provide maintaining the same three dimensional structure as the 100% identity *over the full length of SEQ ID NO:6*” (Office Action of 12/19/03 at page 6, emphasis in original), Applicants submit that the claims at issue do not describe a broad genus. Furthermore, Applicants need not establish that the three-dimensional structure of each variant will be the same as that of the protein encoded by SEQ ID NO:6 in order to enable the claimed variants. One of ordinary skill would be able to use the claimed polypeptide variants in toxicology studies regardless of their three-dimensional structure.

The claims at issue do not describe a genus which could be characterized as “highly variant.” Available evidence illustrates that the claimed genus is of narrow scope.

In support of this assertion, the Examiner’s attention is directed to the reference by Brenner et al. (“Assessing sequence comparison methods with reliable structurally identified distant evolutionary relationships,” Proc. Natl. Acad. Sci. USA (1998) 95:6073-6078), (Reference No. 11, enclosed herewith). Through exhaustive analysis of a data set of proteins with known structural and functional relationships and with <40% overall sequence identity, Brenner et al. have determined that 30% identity is a reliable threshold for establishing evolutionary homology between two sequences aligned over at least 150 residues. (Brenner et al., pages 6073 and 6076.) Furthermore, local identity is particularly important in this case for assessing the significance of the alignments, as Brenner et al. further report that ≥40% identity over at least 70 residues is reliable in signifying homology between proteins. (Brenner et al., page 6076.)

The present application is directed, *inter alia*, to immunoglobulin proteins related to the amino acid sequence of SEQ ID NO:6. In accordance with Brenner et al., naturally occurring molecules may exist which could be characterized as immunoglobulin proteins and which have as little as 30% identity over at least 150 residues to SEQ ID NO:6. The “variant language” of the present claims recites, for example, an isolated polypeptide comprising an amino acid sequence that is “a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:6” (note that SEQ ID NO:6 has 310 amino acid residues). This variation is far less than that of all potential immunoglobulin proteins related to SEQ ID NO:6, i.e., those immunoglobulin proteins having as little as 30% identity over at least 150 residues to SEQ ID NO:1. Moreover, such variation, either a polypeptide having an

amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO:6 or a biologically active or immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:6, is orders of magnitude less than the alleged subsequences alleged by the Examiner. An assertion otherwise ignores that such variants and biologically active and immunogenic fragments are naturally occurring.

All that is necessary to satisfy the enablement requirement of 35 U.S.C. § 112, first paragraph, is that a skilled artisan would reasonably understand how to make and use the claimed polypeptides, without undue experimentation.

In sum, Applicants disclosure as filed discloses information sufficient to permit a skilled artisan to make the claimed polypeptides, variants and biologically active and immunogenic fragments thereof. Accordingly, the Specification would allow one of skill in the art to practice the full scope of what is claimed.

As set forth in *In re Marzocchi*, 169 USPQ 367, 369 (CCPA 1971):

The first paragraph of § 112 requires nothing more than objective enablement. How such a teaching is set forth, either by the use of illustrative examples or by broad terminology, is of no importance.

As a matter of Patent Office practice, then, a specification disclosure which contains a teaching of the manner and process of making and using the invention in terms which correspond in scope to those used in describing and defining the subject matter sought to be patented *must* be taken as in compliance with the enabling requirement of the first paragraph of § 112 *unless* there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support.

Contrary to the standard set forth in *Marzocchi*, the Examiner has failed to provide any reasons why one would doubt that the guidance provided by the present specification would enable one to make and use the claimed polypeptides and variants of SEQ ID NO:6. Hence, a *prima facie* case for non-enablement has not been established with respect to the claimed polypeptides and variants of SEQ ID NO:6.

For at least the above reasons, withdrawal of this rejection is requested.

#### Rejection Under 35 U.S.C. §112, first paragraph. Written Description

Claims 21-22, 34, and 32-33 stand rejected under 35 U.S.C. § 112, first paragraph, based on the allegation that the subject matter was not described in the Specification in such a way as to reasonably convey to one of skill in the art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Office Action asserts that:

- Applicant has disclosed only SEQ ID NO:6, therefore, the skilled artisan cannot envision all the contemplated amino acid sequence possibilities recited in the instant claims. . . Likewise, Applicant fails to satisfy the written-description requirement where the claimed invention called for a “naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:6” and “a polypeptide having an immunogenic/biologically active fragment” of SEQ ID NO:6, but did not disclose such “variants” and “fragments.” (Office Action of 12/31/03, page 7);
- ...the claimed polypeptides are defined only by their homology to SEQ ID NO:6, which is insufficient to satisfy 112(1) since “a mere wish or plan” for obtaining an invention is not enough to comply with 112(1). (Office Action of 12/31/03, page 8);

These rejections are respectfully traversed.

The requirements necessary to fulfill the written description requirement of 35 U.S.C. 112, first paragraph, are well established by case law.

... the applicant must also convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the “written description” inquiry, *whatever is now claimed*. *Vas-Cath, Inc. v. Mahurkar*, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991)

... Mention of representative compounds encompassed by generic claim language *clearly is not required by Section 112 or any other provision of the statute*. But, where no explicit description of a generic invention is to be found in the specification...mention of representative compounds may provide an implicit description upon which to base generic claim language. *In re Robins*, 429 F.2d 452, 456-57, 166 USPQ 552, 555 (CCPA 1970) [emphasis added]

... [I]t has been consistently held that the naming of one member of such a group is not, in itself, a proper basis for a claim to the entire group. However, *it may not be necessary to enumerate a plurality of species if a genus is sufficiently*

*identified in an application by ‘other appropriate language.’* *In re Grimme*,  
274 F.2d 949, 952, 124 USPQ 499, 501 (CCPA 1960) [emphasis added]

Attention is also drawn to the Patent and Trademark Office’s own “Guidelines for Examination of Patent Applications Under the 35 U.S.C. Sec. 112, para. 1”, published January 5, 2001, which provide that:

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., ***complete or partial structure***, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics. What is conventional or well known to one of ordinary skill in the art need not be disclosed in detail. ***If a skilled artisan would have understood the inventor to be in possession of the claimed invention at the time of filing, even if every nuance of the claims is not explicitly described in the specification, then the adequate description requirement is met.*** [footnotes omitted, emphasis added]

Thus, the written description standard is fulfilled by both what is specifically disclosed and what is conventional or well known to one skilled in the art.

**A. The Specification Provides an Adequate Written Description of the Claimed “Variants” of SEQ ID NO:1**

SEQ ID NO:6 is specifically disclosed in the application (see, for example, the Sequence Listing). Polypeptide variants having at least 90% identity to SEQ ID NO:6 are described, for example, at page 22, lines 2-5. Moreover, the Specification at page 8, lines 21-23, defines “IGFAM” as “the amino acid sequences of substantially purified IGFAM obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.” Hence, by referring to “a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:6 it is apparent that the inventors contemplated naturally occurring variants of SEQ ID NO:6 as opposed to variants created *in vitro*, i.e., those variants known to one of skill in the art to be synthesized, semi-synthesized or produced by recombinant methodologies.

Additionally, the term “naturally occurring” is a well-known term in the art which Applicants

intended to be used in such context. As such, no further definition of the term is necessary (MPEP 2163 II A3(a)):

What is conventional or well known to one of ordinary skill in the art need not be disclosed in detail. See *Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d at 1384, 231 USPQ at 94. If a skilled artisan would have understood the inventor to be in possession of the claimed invention at the time of filing, even if every nuance of the claims is not explicitly described in the specification, then the adequate description requirement is met. See, e.g., *Vas-Cath*, 935 F.2d at 1563, 19 USPQ2d at 1116; *Martin v. Johnson*, 454 F.2d 746, 751, 172 USPQ 391, 395 (CCPA 1972) (stating “the description need not be in *ipsis verbis* [i.e., “in the same words”] to be sufficient”).

One of ordinary skill in the art would recognize that “*a naturally occurring amino acid sequence*” as recited in claim 21 is one which occurs in nature. Through the process of natural selection, nature will have determined the appropriate amino acid sequences. Given the information provided by SEQ ID NO:6 (the amino acid sequence of IGFAM-6) and SEQ ID NO:25 (the polynucleotide sequence encoding IGFAM-6), one of skill in the art would be able to routinely obtain “a naturally-occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:6.” For example, the identification of relevant polynucleotides could be performed by hybridization and/or PCR techniques that were well-known to those skilled in the art at the time the subject application was filed and/or described throughout the Specification of the instant application. For example:

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-19 and fragments thereof.. (Specification at page 6, lines 9-14.)

“Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of identity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with

more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Generally, such wash temperatures are selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions for nucleic acid hybridization are well known and can be found in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9. (Specification at page 15, line 29 through page 16, line 14.)

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:20-38 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) (Specification at page 23, lines 7-11.)

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding IGFAM or closely related molecules may be used to identify nucleic acid sequences which encode IGFAM. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding IGFAM, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the IGFAM encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:20-38 or from genomic sequences including promoters, enhancers, and introns of the IGFAM gene. (Specification at page 40, lines 13 to 25.)

See also Example VI at page 50.

In order to make the claimed polypeptides, one skilled in the art need only screen a cDNA library or use appropriate PCR conditions to identify relevant polynucleotides/polypeptides that already exist in nature. By adjusting the nature of the probe or nucleic acid (*i.e.*, non-conserved, conserved or highly conserved) and the conditions of hybridization (maximum, high, intermediate or low stringency), one can obtain variant polynucleotides of SEQ ID NO:25 which, in turn, will allow one to make the variant polypeptides of SEQ ID NO:6 recited by the present claims. Conventional methods for making polypeptides, such as those methods described at page 25, lines 6-14 of the Specification, could be used to make the recited polypeptide variants.

Thus, not only can one of ordinary skill in the art based on hybridization results, predict, detect and isolate with a high level of certainty, the presence or absence of a polynucleotide sequence encoding a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:6, the skilled artisan is also able to compare the encoded polypeptide sequence to SEQ ID NO:6 to determine the percentage identity of said polypeptide sequence to SEQ ID NO:6. Such methods for isolating, cloning, expressing and comparing polynucleotides and their encoded polypeptides are routine analyses for the skilled artisan in the field of recombinant molecular biology.

Accordingly, the Specification provides an adequate written description of the recited variants.

**1. The present claims specifically define the claimed genus through the recitation of chemical structure**

Court cases in which “DNA claims” have been at issue (which are hence relevant to claims to proteins encoded by the DNA) commonly emphasize that the recitation of structural features or chemical or physical properties are important factors to consider in a written description analysis of such claims. For example, in *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993), the court stated that:

If a conception of a DNA requires a precise definition, such as by structure, formula, chemical name or physical properties, as we have held, then a description also requires that degree of specificity.

In a number of instances in which claims to DNA have been found invalid, the courts have noted that the claims attempted to define the claimed DNA in terms of functional characteristics without

any reference to structural features. As set forth by the court in *University of California v. Eli Lilly and Co.*, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997):

In claims to genetic material, however, a generic statement such as “vertebrate insulin cDNA” or “mammalian insulin cDNA,” without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function.

Thus, the mere recitation of functional characteristics of a DNA, without the definition of structural features, has been a common basis by which courts have found invalid claims to DNA. For example, in *Lilly*, 43 USPQ2d at 1407, the court found invalid for violation of the written description requirement the following claim of U.S. Patent No. 4,652,525:

1. A recombinant plasmid replicable in prokaryotic host containing within its nucleotide sequence a subsequence having the structure of the reverse transcript of an mRNA of a vertebrate, which mRNA encodes insulin.

In *Fiers*, 25 USPQ2d at 1603, the parties were in an interference involving the following count:

A DNA which consists essentially of a DNA which codes for a human fibroblast interferon-beta polypeptide.

Party Revel in the *Fiers* case argued that its foreign priority application contained an adequate written description of the DNA of the count because that application mentioned a potential method for isolating the DNA. The Revel priority application, however, did not have a description of any particular DNA structure corresponding to the DNA of the count. The court therefore found that the Revel priority application lacked an adequate written description of the subject matter of the count.

Thus, in *Lilly* and *Fiers*, nucleic acids were defined on the basis of functional characteristics and were found not to comply with the written description requirement of 35 U.S.C. §112; *i.e.*, “an mRNA of a vertebrate, which mRNA encodes insulin” in *Lilly*, and “DNA which codes for a human fibroblast interferon-beta polypeptide” in *Fiers*. In contrast to the situation in *Lilly* and *Fiers*, the claims at issue in the present application define polypeptides of SEQ ID NO:6 in terms of chemical structure, rather than in terms of functional characteristics. For example, the “variant language” of independent claim 21 recites chemical structure to define the claimed genus:

1. An isolated polypeptide sequence selected from the group consisting of . . . b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical

to an amino acid sequence selected from the group consisting of . . . SEQ ID NO:6 . . .

From the above it should be apparent that the claims of the subject application are fundamentally different from those found invalid in *Lilly* and *Fiers*. The subject matter of the present claims is defined in terms of the chemical structure of SEQ ID NO:6. In the present case, there is no reliance merely on a description of functional characteristics of the claimed polypeptides. The polypeptides defined in the claims of the present application recite structural features of the polypeptide of SEQ ID NO:6, and cases such as *Lilly* and *Fiers* stress that the recitation of structure is an important factor to consider in a written description analysis of claims of this type. By failing to base its written description inquiry “on whatever is now claimed,” the Examiner failed to provide an appropriate analysis of the present claims and how they differ from those found not to satisfy the written description requirement in *Lilly* and *Fiers*.

**2. The present claims do not define a genus which is “highly variant”**

Furthermore, the claims at issue do not describe a genus which could be characterized as “highly variant” as present *supra* in reference to the “claimed genus of fragments and polypeptide that have at least 90% sequence identity of SEQ ID NO:6” (Office Action of 12/31/03, page 8).

**3. IGFAM proteins contain Ig domains which are known to function in DNA binding**

Applicants have adequately described the instant invention in terms of a method of its making together with providing both structural and functional characteristics and have provided evidence of a correlation between structure and function. Conventional methods for making the claimed polypeptides, are described at page 25, lines 6-14 of the Specification. Applicants have identified SEQ ID NO:6 as an immunoglobulin superfamily protein, IGFAM-6 protein (see Specification, page 5, lines 26-30), which is identified as having sequence homology to JAM (Specification, page 60, Table 2, column 6). The Specification teaches that a new member of the immunoglobulin superfamily, JAM, contains two Ig domains and that JAM is situated at tight junctions which occur between adjacent epithelial or endothelial cells. JAM appears to play a structural role in the control of monocyte migration across epithelium or endothelium to sites of inflammation (Specification, page 4, lines 11-16) and the Specification identifies the presence of Ig domains within SEQ ID NO:6 (Specification, page 60,

column 5). Thus, SEQ ID NO:6, having Ig domains, would be understood to function in the control of monocyte migration across epithelium or endothelium to sites of inflammation.

The MPEP states that:

The claimed invention as a whole may not be adequately described where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. (MPEP § 2163 I. A, Rev. 1, Feb. 2003, p. 2100-161).

In contrast, the instant invention is adequately described as claimed and is described in terms of the correlation of structure and function, as one of skill in the art would recognize that Ig domains correlate with a structural role in the control of monocyte migration across epithelium or endothelium.

In support of this position, Applicants respectfully bring to the attention of the Examiner that the specification teaches that a “monoclonal antibody (mAb) directed against JAM inhibited transmigration of monocytes across endothelial cell layers *in vitro* and that systemic administration of this mAb to mice prevented recruitment of monocytes to sites of inflammation (see Specification, page 4, lines 15-18). Thus, Applicants have provided an art-recognized correlation between the Ig domain, a structural domain within the claimed invention, and the function of the Ig domain within JAM and so too, more likely than not, the Ig domain of IGFAM-6 functions in the control of monocyte migration across epithelium or endothelium.

One of skill in the art would conclude that in order to have control of monocyte migration across epithelium or endothelium, 90% variants and biologically active and immunogenic fragments of SEQ ID NO:6 would have the Ig domains as structural domains of 90% variants and biologically active and immunogenic fragments of SEQ ID NO:6 in order to maintain control of monocyte migration across epithelium or endothelium. Therefore, one of ordinary skill in the art would conclude that Applicants have provided an adequate description of SEQ ID NO:6 and variants thereof as well as biologically active and immunogenic fragments of SEQ ID NO:6 in terms of the correlation of the Ig domains, a structural component of SEQ ID NO:6, 90% variants and biologically active and immunogenic fragments thereof which are involved in the control of monocyte migration across epithelium or endothelium of the claimed invention.

**4. The state of the art at the time of the present invention is further advanced than at the time of the *Lilly* and *Fiers* applications**

In the *Lilly* case, claims of U.S. Patent No. 4,652,525 were found invalid for failing to comply

with the written description requirement of 35 U.S.C. §112. The '525 patent claimed the benefit of priority of two applications, Application Serial No. 801,343 filed May 27, 1977, and Application Serial No. 805,023 filed June 9, 1977. In the *Fiers* case, party Revel claimed the benefit of priority of an Israeli application filed on November 21, 1979. Thus, the written description inquiry in those case was based on the state of the art at essentially at the "dark ages" of recombinant DNA technology.

The present application has a priority date of 22 December 1998. Much has happened in the development of recombinant DNA technology in the 17 or more years from the time of filing of the applications involved in *Lilly* and *Fiers* and the present application. For example, the technique of polymerase chain reaction (PCR) was invented. Highly efficient cloning and DNA sequencing technology has been developed. Large databases of protein and nucleotide sequences have been compiled. Much of the raw material of the human and other genomes has been sequenced. With these remarkable advances one of skill in the art would recognize that, given the sequence information of SEQ ID NO:6 and the additional extensive detail provided by the subject application, the present inventors were in possession of the polypeptide variants and fragments recited by the claims at the time of filing of this application.

## **5. Summary**

The Office Action failed to base its written description inquiry "on whatever is now claimed." Consequently, the Action did not provide an appropriate analysis of the present claims and how they differ from those found not to satisfy the written description requirement in cases such as *Lilly* and *Fiers*. In particular, the claims of the subject application are fundamentally different from those found invalid in *Lilly* and *Fiers*. The subject matter of the present claims is defined in terms of the chemical structure of SEQ ID NO:6, including Ig domains known to one of skill in the art to function in control of monocyte migration across epithelium or endothelium. The courts have stressed that structural features are important factors to consider in a written description analysis of claims to nucleic acids and proteins. In addition, the genus of polypeptides defined by the present claims is adequately described, as evidenced by Brenner et al. Additionally, 90% variants and biologically active immunogenic fragments of SEQ ID NO:6 are adequately described, as evidenced by the Specification. Furthermore, there have been remarkable advances in the state of the art since the *Lilly* and *Fiers* cases, and these advances were given no consideration whatsoever in the position set forth by the Office Action.

For at least the above reasons it is believed that claims 21-22, 24, and 32-33 meet the written

description requirement of 35 U.S.C. § 112, first paragraph. It is therefore requested that this rejection be withdrawn.

CONCLUSION


In light of the above amendments and remarks, Applicants submit that the present application is fully in condition for allowance, and request that the Examiner withdraw the outstanding rejections. Early notice to that effect is earnestly solicited.

If the Examiner contemplates other action, or if a telephone conference would expedite allowance of the claims, Applicants invite the Examiner to contact Applicants' Attorney at (650) 855-0555.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108.

Respectfully submitted,  
INCYTE CORPORATION

Date: March 31, 2004

  
\_\_\_\_\_  
Shirley A. Recipon  
Reg. No. 47,016  
Direct Dial Telephone: (650) 621-8555

Customer No.: 27904  
3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886

Enclosures:

Declaration of John C. Rockett, Ph.D., under 37 C.F.R. § 1.132, with attached Exhibits A-Q

Declaration of Vishwanath R. Iyer, Ph.D., under 37 C.F.R. § 1.132 with Exhibits A-E

Declaration of Tod Bedilion, Ph.D., under 37 C.F.R. § 1.132

**21 references:**

1. PCT application WO 95/21944, SmithKline Beecham Corporation, Differentially expressed genes in healthy and diseased subjects (August 17, 1995)

2. PCT application WO 95/20681, Incyte Pharmaceuticals, Inc., Comparative gene transcript analysis (August 3, 1995)
3. M. Schena et al., Quantitative monitoring of gene expression patterns with a complementary DNA microarray, Science 270:467-470 (October 20, 1995)
4. PCT application WO 95/35505, Stanford University, Method and apparatus for fabricating microarrays of biological samples (December 28, 1995)
5. U.S. Pat. No. 5,569,588, M. Ashby et al., Methods for drug screening (October 29, 1996)
6. R. A. Heller et al., Discovery and analysis of inflammatory disease-related genes using cDNA microarrays, Proc. Natl. Acad. Sci. USA 94:2150 - 2155 (March 1997)
7. PCT application WO 97/13877, Lynx Therapeutics, Inc., Measurement of gene expression profiles in toxicity determinations (April 17, 1997)
8. Acacia Biosciences Press Release (August 11, 1997)
9. V. Glaser, Strategies for Target Validation Streamline Evaluation of Leads, Genetic Engineering News (September 15, 1997)
10. J. L. DeRisi et al., Exploring the metabolic and genetic control of gene expression on a genomic scale, Science 278:680 - 686 (October 24, 1997)
11. S. E. Brenner et al., Assessing sequence comparison methods with reliable structurally identified distant evolutionary relationships, Proc. Natl. Acad. Sci. U.S.A. 95:6073-78 (1998)
12. N. L. Anderson, et al., A two-dimensional gel database of rat liver proteins useful in gene regulation and drug effects studies, Electrophoresis, 12:907-930 (1991)
13. N. L. Anderson, et al., An updated two-dimensional gel database of rat liver proteins useful in gene regulation and drug effect studies, Electrophoresis, 16:1977-1981 (1995)
14. M. R. Wilkins, et al., Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it, Biotechnology and Genetic Engineering Reviews, 13: 19-50 (1995)
15. J. E. Celis, et al., Human cellular protein patterns and their link to genome DNA sequence data: usefulness of two-dimensional gel electrophoresis and microsequencing, FASEB Journal, 5: 2200-2208 (1991)
16. B. Franzen, et al., Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis, 14: 1045-1053 (1993)
17. B. Bjellqvist, et al., Reference points for comparisons of two-dimensional maps of proteins from different human cell types defined in a pH scale where isoelectric points correlate with polypeptide compositions, Electrophoresis, 15: 529-539 (1994)
18. Large Scale Biology Company Info; LSB and LSP information; from <http://www.lsbc.com> (2001)
19. E. F. Nuwaysir, et al., Microarrays and Toxicology: The Advent of Toxicogenomics, Molecular Carcinogenesis 24:153-159 (1999)
20. S. Steiner and N. L. Anderson, Expression profiling in toxicology -- potentials and limitations, Toxicology Letters 112-13:467-471 (2000)
21. Email from the primary investigator, Dr. Cynthia Afshari to an Incyte employee, dated July 3, 2000, as well as the original message to which she was responding